SCODiA Report by MLBI Lab

Single-Cell Transcriptomic and Genomic Landscape of the Renal Cell Carcinoma Microenvironment

This report provides a comprehensive single-cell analysis of human kidney tissue, contrasting normal and renal cell carcinoma (RCC) samples. It identifies malignant renal epithelial cells through aneuploidy and distinct gene expression. The study reveals a dynamically reprogrammed tumor immune microenvironment marked by increased regulatory T cells and a shift towards M1-like macrophages. Crucially, it highlights extensive cell-cell communication alterations, including prominent angiogenesis, immune evasion mechanisms, and activation of oncogenic pathways within the tumor.

Contents

0. Dataset overview
1. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy
2. Major Cell Type Score and Annotation Mapping on UMAP
3. Overall Celltype_subset Marker Expression Analysis for Kidney Tissue
4. Genomic Copy Number Variation Analysis in Renal Epithelial and Unassigned Cells
5. CNV-Based UMAP Visualization of Renal Cells
6. Minor Cell Type Population Analysis in Kidney Tumor and Normal Tissues
7. T Cell Subset Population Analysis in Kidney Normal and Tumor Samples
8. Differential Proportion of Regulatory T Cells (Tregs) in Kidney Tumor vs. Normal Tissue
9. Macrophage Subset Population Analysis in Normal and Tumor Kidney Tissues
10. Ploidy Population Analysis of Tumor Origin and Unassigned Cells in Kidney Samples
11. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tumor Microenvironment
12. Cell-Cell Interaction Analysis by Condition in Kidney Tissue
13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Kidney Tissue
14. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tumor Microenvironment
15. 신장 상피세포의 조건별 표면 마커 분석
16. Macrophage Condition-Specific Surfaceome Markers in Kidney Tissue
17. Condition-Specific Surfaceome Markers in CD4+ T cells in Kidney Tumor Microenvironment
18. Renal Epithelial Cell Gene Ontology Analysis: Insights into Ploidy, Normal Physiology, and Tumorigenesis
19. 신장암 미세환경 내 주요 세포 유형별 유전자 세트 농축 분석
20. Discussion
21. Query List

0. Dataset overview

Dataset Summary

• Data Type: Single-cell RNA-seq data (AnnData format).
• Dimensions: Contains 26,502 cells and 22,483 genes.
• Species & Tissue: The data is from human Kidney tissue.
• Conditions: Includes 'tumor' and 'normal' conditions.
• Cell Types (Major): unassigned, Myeloid cell, T cell, Endothelial cell, Stromal cell, Mast cell, B cell, Renal Epithelial cell.
• Cell Types (Minor): unassigned, Macrophage, T cell CD4+, T cell CD8+, Endothelial cell, Smooth muscle cell, Dendritic cell, Mast cell, Plasma cell, Intercalated cell, Podocyte, Fibroblast, Collecting Duct Principal cell, Thick Ascending Limb, B cell, NK cell, ILC, Proximal Tubule.
• Cell Types (Subset): Provides more granular cell types, such as Macrophage (M1), T cell (Naive), Endothelial tip cell, and various others.
• Tumor Origin Cell Types: 'unassigned' and 'Renal Epithelial cell' are identified as potential tumor origin cell types.
• Ploidy: Cells are categorized as 'Aneuploid' or 'Diploid' based on ploidy_dec.
• Precomputed Results: The dataset includes precomputed results for Cell-Cell Interaction (CCI), Differential Expression Genes (DEG), Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GSA) for various cell types and conditions. It also has CNV estimates and ploidy inference labels.

1. UMAP Visualization of Kidney scRNA-seq Data by Condition, Sample, Cell Type, and Ploidy

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the global transcriptional landscape of 26,502 single cells from human kidney tissue. The UMAPs are colored by various cellular and sample-level annotations: disease 'condition' (tumor vs. normal), individual 'sample', 'celltype_major', 'celltype_minor', 'ploidy_dec' (aneuploidy status), and 'celltype_subset'. These visualizations provide an essential overview of cell clustering, heterogeneity, and the distribution of biological and technical variables across the dataset.

Visual Summary

Condition and Sample Distribution

The UMAP colored by condition (tumor vs. normal) reveals a clear separation between tumor and normal cells. The majority of cells from 'tumor' samples (blue) cluster into several distinct regions, while 'normal' cells (red) form separate clusters, primarily in specific areas of the UMAP. This indicates a strong transcriptional difference between tumor and normal tissue components.

The sample UMAP shows that cells from different individual samples (various colors) are generally well-mixed across many clusters, suggesting good integration of data and that major biological signals, rather than batch effects, drive the global clustering. However, some smaller, more isolated clusters do appear to be dominated by specific samples, which could reflect unique biological features of those patients or minor residual sample-specific effects.

Cell Type Hierarchy and Distribution

The celltype_major, celltype_minor, and celltype_subset UMAPs progressively reveal the cellular heterogeneity within the kidney tissue.

• Celltype_major: Shows distinct clusters for major cell lineages, including Renal Epithelial cells, Myeloid cells, T cells, Endothelial cells, and Stromal cells. Notably, the large clusters identified as 'tumor' in the condition UMAP predominantly align with the 'Renal Epithelial cell' population (light green/yellow). Immune cells (Myeloid, T cells) are also clearly delineated and distributed across various regions, indicating their presence in both normal and tumor microenvironments.
• Celltype_minor: Provides finer granularity, differentiating within major groups, e.g., Macrophages and Dendritic cells within Myeloid cells, CD4+ and CD8+ T cells, and various renal epithelial subtypes like Proximal Tubule, Podocyte, and Collecting Duct Principal cells. This increased resolution highlights the specific types of cells contributing to the identified clusters.
• Celltype_subset: Displays the highest resolution, showing further functional and developmental states, such as Macrophage (M1, M2A-D) subtypes, T cell (Naive, Cytotoxic, Treg, Th) subsets, and distinct segments of the renal tubule (PCT S1_S2, PST S3, PCT_S3). This detailed annotation confirms the robust identification of highly specific cell populations.

Ploidy Status

The ploidy_dec UMAP shows a striking distribution: 'Aneuploid' cells (red) almost exclusively overlap with the 'tumor'-specific clusters and the 'Renal Epithelial cell' clusters observed in the other UMAPs. Conversely, 'Diploid' cells (yellow) are broadly distributed across the clusters associated with normal tissue and the immune/stromal populations found in both conditions. A small fraction of cells are labeled 'Unclear' (purple) and are scattered throughout the UMAP.

Biological Interpretation

1. Malignant Cell Identification and Origin: The distinct separation of 'tumor' cells from 'normal' cells, coupled with the enrichment of 'Aneuploid' cells within these tumor clusters, strongly indicates the presence of malignant cells. The observation that these tumor-associated, aneuploid cells are primarily annotated as 'Renal Epithelial cells' at major and minor levels is consistent with the data context that 'Renal Epithelial cell' is the designated 'Tumor origin celltype'. This confirms the successful capture and identification of kidney tumor cells based on their gene expression and chromosomal instability.
2. Tumor Microenvironment Complexity: While tumor cells form distinct clusters, the presence of various immune cell types (Myeloid, T, B cells) and stromal/endothelial cells in both tumor-enriched and normal regions of the UMAP highlights the complexity of the tumor microenvironment. The diverse subsets, such as M1/M2 macrophages and various T helper/cytotoxic/regulatory T cells, suggest active immune responses and cellular interactions within the tumor, warranting further investigation into their specific roles and states.
3. Renal Cell Heterogeneity: The detailed celltype_minor and celltype_subset annotations effectively resolve the intricate cellular architecture of the kidney, distinguishing between different segments of the nephron (e.g., Proximal Tubule, Thick Ascending Limb, Collecting Duct Principal Cell, Podocyte) and specialized interstitial cells (e.g., Fibroblast, Smooth muscle cell, Endothelial cell). This detailed mapping provides a foundation for understanding condition-specific alterations in each of these cell populations.
4. Annotation Quality and Consistency: The consistent and logical progression of cell type annotations from major to subset levels, along with the clear association of aneuploidy with renal epithelial tumor cells, supports the high quality and biological relevance of the cell type assignments. The presence of 'unassigned' or 'unclear' populations, while small, indicates areas for potential refinement or further characterization.

Annotation Notes

The UMAPs provide a comprehensive visual validation of the dataset's structure and annotation quality. The clear separation by condition and ploidy status, combined with the hierarchical cell type annotations, demonstrates that the embedding effectively captures the major biological distinctions and cellular heterogeneity within the kidney samples. The presence of 'unassigned' cells warrants further investigation to determine their identity or if they represent low-quality cells or transitional states.

2. Major Cell Type Score and Annotation Mapping on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores across the UMAP embedding for single-cell RNA-seq data from human kidney tissue. For each major cell type (T cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Renal Epithelial cell), a continuous score (likely derived from HiCAT, indicating confidence or similarity to that cell type) is projected onto the UMAP. These score maps are then compared with existing discrete annotations for ploidy_dec (aneuploidy status) and celltype_major to assess annotation quality, cell identity, and the overall structure of the dataset.

Visual Summary

The UMAP embeddings reveal distinct clusters of cells.

Cell Type Score Distributions

• T cells: High scores are concentrated in a prominent cluster in the lower-right quadrant and a few smaller, interconnected clusters on the left side of the UMAP.
• B cells: A distinct, compact cluster showing high scores is located towards the upper-left of the UMAP.
• Myeloid cells: A large, somewhat diffuse cluster in the upper-right quadrant exhibits high myeloid cell scores.
• Mast cells: A small, specific cluster showing high mast cell scores is visible near the myeloid cluster.
• Endothelial cells: Several elongated clusters showing high scores are distributed across the UMAP, often forming connections between other larger clusters, which is characteristic of vascular networks.
• Stromal cells: High scores are observed in a few distinct clusters, with some appearing adjacent to endothelial populations.
• Renal Epithelial cells: Large, prominent clusters in the central-left and lower-left regions show high scores for renal epithelial cells.
• Ploidy Status (ploidy_dec): Cells labeled as Aneuploid (dark red) form distinct, separated clusters. These aneuploid clusters appear to primarily overlap with regions identified as having high Renal Epithelial cell scores. Diploid cells (light yellow) are more broadly distributed across various other cell type clusters.
• Major Cell Type Annotation (celltype_major): The discrete celltype_major annotations (colored by cell type) show a strong concordance with the regions of high scores for each corresponding major cell type. For instance, the teal-colored T cell cluster aligns well with the areas of high T cell scores, and the yellow Renal Epithelial cell clusters align with high Renal Epithelial cell scores. The 'unassigned' cells (purple) are scattered but typically reside in areas with generally lower scores across the defined major cell types, or at the boundaries of clusters.

Biological Interpretation

1. High-Quality Cell Type Delineation: The clear spatial separation of distinct cell type scores on the UMAP indicates that the major cell types are well-resolved in this single-cell RNA-seq dataset. The continuous score maps confirm that cells within annotated clusters indeed express gene signatures characteristic of their assigned major cell type.
2. Validation of Existing Annotations: The strong overlap between the HiCAT_major_score plots and the celltype_major annotation provides confidence in the accuracy and robustness of the existing cell type assignments. This suggests that the initial clustering and subsequent annotation process effectively captured the major cell populations.
3. Renal Epithelial Cell Heterogeneity and Aneuploidy: The finding that aneuploid cells predominantly reside within clusters with high Renal Epithelial cell scores is highly significant. Given that "Renal Epithelial cell" is specified as a "Tumor origin celltype" and the dataset includes "tumor" conditions, this strongly suggests that these aneuploid renal epithelial cells represent the malignant tumor cell population. Aneuploidy is a hallmark of many cancers, including renal cell carcinoma, and its co-localization with renal epithelial cells supports their tumor identity.
4. Immune and Stromal Compartment Analysis: The distinct clustering of immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Endothelial cells, Stromal cells) allows for focused investigations into their roles in the kidney, particularly in the context of tumor vs. normal conditions. The spatial arrangement of endothelial and stromal cells, often forming interconnected structures, is consistent with their roles in forming the tissue microenvironment and vasculature.

Annotation Notes

The strong concordance between the computed cell type scores and the celltype_major annotation suggests that the current major cell type labels are reliable for downstream analyses. The ploidy_dec annotation clearly distinguishes a population of potentially malignant renal epithelial cells, which is a critical aspect for studying kidney tumor biology. The presence of 'unassigned' cells, while not forming large, distinct clusters, might warrant further investigation to determine if they represent rare cell types, transitional states, or cells with ambiguous transcriptomic profiles.

3. Overall Celltype_subset Marker Expression Analysis for Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression patterns of identified marker genes across various celltype_subset populations derived from single-cell RNA-seq data of kidney tissue. The purpose of this visualization is to validate the distinct molecular identities of the annotated cell subsets by assessing the specificity and abundance of key marker genes. Each row represents a celltype_subset, and each column represents a marker gene. The size of the dot corresponds to the fraction of cells within that group expressing the gene, while the color intensity reflects the mean expression level of the gene in those cells. Markers common to three or more groups were removed to emphasize specificity.

Visual Summary

The dot plot reveals well-defined clusters of highly expressed and specific marker genes for the majority of celltype_subset populations. This is indicated by prominent, large, and dark red dots predominantly aligned along the diagonal, where each cell type displays unique or highly enriched gene expression. Horizontal bands of consistently expressed genes (large, dark red dots) confirm the robust identity of most annotated cell subsets. The presence of these distinct patterns across diverse cell types—ranging from various renal epithelial cells to distinct immune and stromal cell populations—suggests a high degree of confidence in the current celltype_subset annotations. The "Fraction of cells in group (%)" bar on the right side provides context on the relative abundance of each cell type in the dataset.

Biological Interpretation

The marker gene expression patterns strongly support the assigned biological identities for most celltype_subset populations within the kidney tissue.

Renal Epithelial Cells

• Collecting Duct Principal cell: Characterized by specific expression of markers such as HSD11B2, CLDN4, and RHBG. HSD11B2 (11-beta hydroxysteroid dehydrogenase type 2) is critical for mineralocorticoid receptor regulation in the collecting duct, and CLDN4 (Claudin 4) is a tight junction protein, consistent with principal cell function.
• Intercalated cell: Identified by specific expression of proton pump subunits ATP6V1C2 and ATP6V0D2, along with FOXI1, which are canonical markers for intercalated cells involved in acid-base balance in the collecting duct.
• Podocyte: Displays specific expression of OCIAD2 and TMEM61. While NPHS1 and NPHS2 are classical markers, OCIAD2 and TMEM61 also contribute to podocyte identity.
• Proximal Convoluted Tubule S1_S2: Shows enrichment for SLC5A10, ACSM3, and NUDT19, consistent with solute reabsorption functions of the proximal tubule.
• Proximal Straight Tubule S3: Marked by SLC12A1 (NKCC2) and SLC5A3, indicating distinct roles in solute transport within the nephron.
• Thick Ascending Limb: Distinctly identified by UMOD (Uromodulin, Tamm-Horsfall protein) and CLCNKA (chloride channel Ka), both defining features of this segment of the nephron responsible for salt reabsorption.

Immune Cells

• Macrophage (M1): Exhibits markers associated with inflammatory activation, including CD86 and CD83.
• Macrophage (M2A): Identified by canonical anti-inflammatory and tissue repair markers such as MSR1 (CD204) and MRC1 (CD206).
• Macrophage (M2B/M2C): Show distinct markers like SOCS1/SOCS3 for M2B and SPHK1 for M2C, suggesting further functional specialization within macrophage subsets.
• T cell (Cytotoxic): Clearly defined by expression of CD8A, GZMB, and GZMK, indicative of cytotoxic T lymphocyte function.
• T cell (Tfh): Characterized by IL21R, a receptor important for follicular helper T cell function in germinal centers.
• T cell (Th1): Marked by STAT4 and IFNG, key components of Th1 immune responses.
• T cell (Th17): Identified by RORA and CXCR3, which are associated with Th17 differentiation and function.
• T cell (Th2): Displays GATA3 expression, a master regulator of Th2 cell development.
• T cell (Treg): Shows canonical markers FOXP3, CTLA4, and TNFRSF18, confirming their immunosuppressive phenotype.
• DC (Classical): Identified by CD1C, CLEC9A, CADM1, and XCR1, supporting their role in antigen presentation.
• Mast cell: Expresses characteristic markers KIT (CD117), TPSAB1, and SRGN.
• Plasma cell: Distinctly marked by JCHAIN, XBP1, MZB1, and SDC1, reflecting their role in antibody production.

Stromal and Endothelial Cells

• Fibroblast: Demonstrates robust expression of extracellular matrix components like COL6A2, COL1A2, COL1A1, DCN (Decorin), LUM (Lumican), FBLN1, and growth factor receptor PDGFRA, confirming their role in tissue structure and remodeling.
• Smooth muscle cell: Identified by specific expression of contractile proteins such as ACTA2 (alpha-smooth muscle actin), MYL9, TPM2, TAGLN, and MYH11, reflecting their contractile functions.
• Endothelial cell: Shows expression of pan-endothelial markers like THBD (Thrombomodulin), ESM1 (Endothelial cell-specific molecule 1), ANGPT2, and DLL4, consistent with their lining of blood vessels.
• Endothelial tip cell: While sharing some markers with general endothelial cells, this subset likely has enriched expression for pro-angiogenic markers, although these are not as distinctly separated as other cell types in this particular plot.

Overall, the dot plot provides strong evidence for the high quality and distinctiveness of the celltype_subset annotations across the diverse cellular landscape of the kidney tissue.

Annotation Notes

The observed marker gene expression patterns provide robust support for the current celltype_subset annotations. The clear specificity and high expression levels of canonical and subtype-specific markers for most cell populations validate their identities. While some closely related cell types (e.g., Endothelial vs. Endothelial tip, or certain T cell/macrophage subsets) might exhibit partial overlap in some markers, the overall picture indicates well-resolved and biologically meaningful cell types. This analysis confirms that the resolution of cell types at the celltype_subset level is appropriate and well-supported by the transcriptomic data.

4. Genomic Copy Number Variation Analysis in Renal Epithelial and Unassigned Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) within selected populations of renal epithelial cells and unassigned cells from single-cell RNA-seq data. Cells were grouped by sample, and CNVs were estimated as log2(Copy Number Ratio) (log2(CNR)) across genomic spots. The primary goal was to visualize and summarize significant CNV regions, particularly amplifications, to characterize potential tumor-associated genomic instability.

Visual Summary

The analysis presents two key visualizations: a CNV heatmap of log2(CNR) values across the genome and a summary heatmap detailing the frequency of significantly amplified cytogenetic bands per sample, along with their overall frequency.

CNV Heatmap (log2(CNR)):

• The heatmap displays log2(CNR) values for each cell group (sample, with diploid samples explicitly prefixed) across the human genome (chromosomes 1-22). Red indicates genomic amplification (gain), and blue indicates genomic deletion (loss).
• A clear distinction is visible between samples explicitly labeled 'Diploid' (e.g., Diploid SI_18855, Diploid SI_19704) and other samples (e.g., SI_18854, SI_21561). The 'Diploid' samples generally exhibit a quiet genomic landscape with minimal and less intense CNVs, consistent with a normal diploid state.
• In contrast, the non-'Diploid' samples show widespread and often strong CNV signals, predominantly amplifications (red regions). These samples likely represent aneuploid (tumor) cell populations.
• Recurrent Amplifications: Notable recurrent amplifications are observed across multiple non-'Diploid' samples, including regions on chromosome 4q, 5q, 7p, 7q, and 16q.
• Recurrent Deletions: Fewer prominent deletions are observed, but some samples show minor losses, for instance, on chromosome 18.

Summary of Significantly Amplified Copy Number Regions:

• This plot quantifies the frequency of significant amplifications within specific cytogenetic bands across samples. Darker blue indicates higher amplification frequency.
• Several cytogenetic bands show high overall amplification frequencies (right bar chart) and are consistently amplified in multiple non-'Diploid' samples.

Key Amplified Regions:

• 5q regions: 5q22.1, 5q35.1, and 5p12: These regions show high overall amplification frequencies (0.70, 0.70, 0.60 respectively) and are frequently amplified across samples such as SI_18854, SI_21561, SI_22368, SI_22369, SI_22604, SI_23459, and SI_23843.
• 7p/q regions: Particularly 7p13:7q11.23 (EGFR) and 7q36.1:7p23.1, both showing high overall frequencies (0.70 and 0.80, respectively). The explicit mention of EGFR at 7p13 is highly significant.
• 4q35.1:5p12: Another region with high overall amplification frequency (0.70).
• 16q12.1:16q22.1: This region also exhibits considerable amplification frequency (0.50).
• The samples (e.g., SI_19703, SI_21255, SI_22605) that appeared largely 'Diploid' in the heatmap also show very low or no significant amplifications in this summary, indicating good concordance between the two visualizations.

Biological Interpretation

The CNV analysis provides compelling evidence of widespread genomic instability in a subset of the analyzed samples, particularly within the 'Renal Epithelial cell' (designated as tumor origin) and 'unassigned' populations. The distinct CNV profiles observed strongly differentiate between what appear to be normal/diploid cells and aneuploid/tumor cells.

The observed recurrent amplifications are biologically significant:

• EGFR Amplification (7p13:7q11.23): The amplification of the Epidermal Growth Factor Receptor (EGFR) gene is a well-established oncogenic event across various cancers, including certain renal cell carcinomas [1, 2]. EGFR activation drives cell proliferation, inhibits apoptosis, and promotes angiogenesis and metastasis, making it a critical driver in tumor progression.
• Chromosomal 5q Amplifications: Recurrent gains on chromosome 5q are frequently reported in clear cell renal cell carcinoma (ccRCC) and other solid tumors. This region harbors several genes involved in cell growth, differentiation, and survival, and its amplification can contribute to tumorigenesis [3].
• Other Recurrent Amplifications (4q, 7q, 16q): These regions are also known to contain oncogenes or regulatory elements whose amplification can confer a selective advantage to cancer cells. For instance, specific amplifications on 4q have been implicated in cell cycle regulation, and gains on 16q, while less common than deletions in some cancers, can also contribute to an oncogenic phenotype.

The presence of significant CNVs, especially recurrent amplifications of known oncogenes like EGFR, in the 'Renal Epithelial cell' (tumor origin) and 'unassigned' cell populations strongly supports their malignant identity. The clear separation based on ploidy inference (ploidy_dec column in obs) further validates the identification of tumor-like cells within the dataset.

Clinical or Translational Implications

The identification of recurrent and significant CNVs, particularly EGFR amplification, holds important clinical and translational implications:

• Biomarker for Malignancy: The distinct CNV patterns can serve as robust biomarkers for identifying malignant cells, especially in cases where cell morphology or standard histological markers might be ambiguous or limited in single-cell resolution.
• Potential Therapeutic Targets: EGFR is a validated therapeutic target in several cancers, with various EGFR inhibitors available [4]. Its amplification in these renal tumor samples suggests that patients with similar genomic profiles might benefit from EGFR-targeted therapies. Further functional studies would be necessary to confirm the oncogenic dependency on EGFR in this specific context.
• Understanding Tumor Heterogeneity: The sample-specific differences in CNV patterns, even within aneuploid groups, highlight the genomic heterogeneity of renal tumors. This insight is crucial for personalized treatment strategies, as different patients (and even different tumor subclones within a patient) might respond differently to therapies based on their unique genomic alterations.

---

References:

1. EGFR amplification in cancer: PubMed search for "EGFR amplification cancer" https://pubmed.ncbi.nlm.nih.gov/?term=EGFR+amplification+cancer
2. EGFR in renal cell carcinoma: PubMed search for "EGFR renal cell carcinoma amplification" https://pubmed.ncbi.nlm.nih.gov/?term=EGFR+renal+cell+carcinoma+amplification
3. Chromosomal aberrations in renal cell carcinoma: PubMed search for "renal cell carcinoma chromosomal amplification 5q" https://pubmed.ncbi.nlm.nih.gov/?term=renal+cell+carcinoma+chromosomal+amplification+5q
4. EGFR inhibitors: PubMed search for "EGFR inhibitors" https://pubmed.ncbi.nlm.nih.gov/?term=EGFR+inhibitors

5. CNV-Based UMAP Visualization of Renal Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a Uniform Manifold Approximation and Projection (UMAP) embedding of single-cell RNA-seq data, where the embedding space is generated based on inferred Copy Number Variation (CNV) profiles (obsm['X_cnv']). The UMAP plots are colored by various metadata features including major cell type, minor cell type, ploidy status, condition (tumor/normal), and individual sample IDs. The primary goal is to visualize how CNV patterns stratify cell populations and to assess the consistency of cell type annotations, ploidy calls, and condition associations within this CNV-driven embedding.

Visual Summary

The UMAP plots reveal a clear separation of cell populations driven by their underlying CNV profiles.

• Overall Embedding Structure: The CNV-based UMAP displays distinct clusters. A large, relatively cohesive central cluster is visible, surrounded by several smaller, more dispersed clusters.

Cell Type Distribution (celltype_major, celltype_minor)

• The major cell types, particularly 'Renal Epithelial cell' (light yellow in celltype_major), form prominent, somewhat fragmented clusters that are distinct from other stromal and immune cell populations (e.g., 'T cell', 'Myeloid cell', 'Endothelial cell').
• Zooming into celltype_minor, specific renal epithelial subtypes like 'Proximal Tubule', 'Collecting Duct Principal cell', and 'Podocyte' contribute to the larger 'Renal Epithelial cell' clusters.
• Immune cells (e.g., 'T cell CD4+', 'T cell CD8+', 'Macrophage', 'Dendritic cell') and stromal cells (e.g., 'Fibroblast', 'Smooth muscle cell', 'Endothelial cell') generally cluster together in the larger, more contiguous central region of the UMAP.
• 'Unassigned' cells are scattered but tend to co-localize with specific cell types, suggesting they might be misannotated or represent transitional states.

Ploidy Status (ploidy_dec)

• A striking pattern emerges with ploidy. The vast majority of cells in the large central cluster are labeled 'Diploid' (light yellow).
• Conversely, distinct peripheral clusters, particularly those associated with the 'Renal Epithelial cell' type, are almost exclusively labeled 'Aneuploid' (dark red). This indicates that the CNV-based UMAP effectively separates cells based on their overall genomic ploidy status.

Condition Distribution (condition)

• Cells from 'normal' tissue (dark red) predominantly occupy the large central region, largely overlapping with the 'Diploid' cell populations.
• Cells from 'tumor' tissue (dark purple) are widely distributed. Critically, the 'Aneuploid' clusters are almost entirely composed of cells from 'tumor' samples, strongly suggesting these are the malignant cells. The presence of 'tumor' cells within the central 'Diploid' region is expected, as tumor samples contain infiltrating immune cells, stromal cells, and potentially normal renal epithelial cells from the tumor microenvironment.

Sample Distribution (sample)

• Within the large 'Diploid' central cluster, cells from different samples (indicated by various colors) appear to be well-mixed, suggesting minimal batch effects related to CNV profiles among non-malignant cells.
• However, within the 'Aneuploid' clusters, some smaller sub-clusters show dominance by specific individual samples (e.g., SI_18854, SI_18855, SI_23843). This highlights inter-patient heterogeneity in the specific CNV patterns observed in tumor cells.

Biological Interpretation

The CNV-based UMAP provides robust evidence for distinguishing malignant renal epithelial cells from other cell types, including tumor-infiltrating immune and stromal cells, and normal kidney cells.

1. Malignant Cell Identification: The strong correlation between 'Aneuploid' status, 'tumor' condition, and specific 'Renal Epithelial cell' clusters strongly indicates that these aneuploid renal epithelial cells represent the malignant population. This aligns with the understanding that cancer cells often exhibit significant genomic instability and aneuploidy.
2. Tumor Microenvironment Composition: The large central cluster comprising diploid cells from both 'normal' and 'tumor' conditions confirms the presence of non-malignant cells (immune cells, endothelial cells, fibroblasts, and normal kidney epithelial cells) within the tumor microenvironment. These cells, even when residing within a tumor, largely maintain a diploid genomic state, distinct from the aneuploid tumor cells.
3. Cell Type Annotation Validation: The clear segregation of major and minor cell types in the CNV embedding, especially the distinction between renal epithelial cells and others, reinforces the quality and accuracy of the cell type annotations. The method effectively leverages CNV signals to group biologically similar cells.
4. Inter-patient Heterogeneity: The sample-specific clustering within the aneuploid populations suggests that while a common feature of malignancy is aneuploidy, the precise patterns of CNVs can vary significantly between individual patients' tumors. This emphasizes the heterogeneous nature of cancer at the genomic level.
5. Utility of CNV Embedding: This analysis demonstrates the power of CNV inference from single-cell RNA-seq data for identifying and characterizing tumor cells, especially in complex tissues like kidney, where tumor cells can be mixed with various normal cell types. The embedding effectively isolates cells with aberrant genomic content.

Annotation Notes

The CNV-based UMAP serves as a valuable quality control and validation step for cell type annotation and disease state assignment. The distinct clustering of aneuploid cells associated with the tumor condition and specific epithelial cell types strongly supports their identification as malignant cells. This robust separation provides confidence in downstream analyses that may focus on these specific populations. The mixed distribution of 'unassigned' cells suggests that further investigation into their identity might be warranted, potentially leveraging their CNV profiles to refine their annotation.

6. Minor Cell Type Population Analysis in Kidney Tumor and Normal Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis provides a population bar plot illustrating the relative abundance of minor cell types across individual samples, distinguishing between normal kidney tissue and renal tumor tissue. The visualization allows for a direct comparison of cellular composition shifts associated with the disease state.

Visual Summary

The stacked bar plot effectively compares the cellular composition of normal (left panel) and tumor (right panel) kidney samples at the minor cell type resolution.

Key visual observations:

• Normal Samples (e.g., SI_21255, SI_22369): These samples are largely dominated by various kidney-specific epithelial cells, notably Proximal Tubule (light green), Thick Ascending Limb (dark blue), Collecting Duct Principal cell (dark red), and Intercalated cell (orange-yellow). Endothelial cells (red-orange) and Fibroblasts (orange) are also consistently present. Immune cell populations such as Macrophages (pale yellow) and T cells (light blue/teal) are present in smaller, albeit variable, proportions.
• Tumor Samples (e.g., SI_22604, SI_18854, SI_21561): A striking feature across most tumor samples is the substantial proportion of 'unassigned' cells (dark blue). In several tumor samples (e.g., SI_22604, SI_18854, SI_21561), these 'unassigned' cells represent the largest cellular component, often exceeding 50% of the total cells.
• Depletion of Normal Renal Epithelial Cells in Tumors: Corresponding to the increase in 'unassigned' cells, the proportions of normal kidney-specific epithelial cells (e.g., Proximal Tubule, Thick Ascending Limb, Collecting Duct Principal cell, Intercalated cell) appear significantly reduced or absent in most tumor samples compared to normal tissue.
• Immune Cell Infiltration in Tumors: Immune cell populations, particularly Macrophages (pale yellow) and T cells (CD4+ and CD8+, light blue/teal), appear more prominent and variable across tumor samples. Macrophages, for instance, constitute a considerable fraction in samples like SI_22368, SI_23843, and SI_19703. Dendritic cells (red) are also noted.
• Sample Heterogeneity: Both normal and tumor groups exhibit sample-to-sample variability in cell type proportions, though the overall trends described above are clear.

Biological Interpretation

1. Disruption of Normal Renal Architecture: The observed reduction in diverse renal epithelial cell types (Proximal Tubule, Thick Ascending Limb, Collecting Duct Principal cell, Intercalated cell, Podocyte) in tumor samples reflects the pathological replacement of healthy kidney parenchyma by malignant cells during tumor progression. This is a fundamental characteristic of solid tumors, where normal tissue structures are often effaced.
2. Prevalence of 'Unassigned' Cells Likely Represents Tumor Cells: The high proportion of 'unassigned' cells in tumor samples is a critical finding. Given that the Tumor origin celltype is specified as 'Renal Epithelial cell' in the data context, it is highly probable that these 'unassigned' cells largely represent the malignant renal epithelial cells. These cells may have undergone significant transcriptional changes and dedifferentiation, causing them to deviate from the established transcriptomic profiles of normal minor cell types, hence falling into an 'unassigned' category. Further characterization (e.g., using obsm['X_cnv'] for CNV analysis or obs['ploidy_dec'] for ploidy status) would be crucial to confirm their neoplastic identity.
3. Dynamic Tumor Immune Microenvironment (TME): The increased presence and variability of immune cells, especially Macrophages and T cells (CD4+ and CD8+), in tumor samples indicate an active immune response within the TME. Macrophages are key players in the TME, capable of adopting diverse phenotypes (pro- or anti-tumoral) that influence tumor growth and metastasis [1]. Similarly, T cells are central to anti-tumor immunity, and their presence suggests ongoing immune surveillance or attempts by the host immune system to control the tumor. The heterogeneity in immune cell composition across tumor samples highlights the diverse immune landscapes characteristic of renal cell carcinoma [2].
4. Stromal Remodeling: The consistent presence of Endothelial cells and Fibroblasts in both normal and tumor samples underscores their roles in maintaining tissue structure, vascularization, and supporting the tumor stroma, which is essential for tumor growth and progression.

Clinical or Translational Implications

1. Identification of Tumor Cells: The 'unassigned' cell population represents a prime target for further investigation. Confirming these as tumor cells and characterizing their specific molecular features could provide insights into tumor biology, heterogeneity, and potential therapeutic vulnerabilities specific to these malignant cells. This could also highlight the need for more granular or disease-specific annotations in future analyses.
2. Immunotherapeutic Strategies: The notable infiltration of immune cells, particularly Macrophages and T cells, in the TME of kidney tumors suggests that immunotherapeutic approaches, such as checkpoint blockade, could be effective in these patients. A deeper understanding of the specific phenotypes and functional states of these immune cells (e.g., pro-inflammatory vs. immunosuppressive macrophages, exhausted vs. activated T cells) is essential to optimize patient stratification and treatment selection [3].
3. Biomarker Development: The distinct shifts in cell type proportions between normal and tumor tissues, especially the relative enrichment of specific immune populations, could yield novel prognostic or predictive biomarkers for kidney cancer. For example, the abundance of certain immune cell subsets could correlate with patient response to specific therapies.

---

References

1. Cassetta, L., & Pollard, J. W. (2018). Targeting macrophages: therapeutic approaches in cancer. *Nature Reviews Drug Discovery*, 17(12), 887-904. https://pubmed.ncbi.nlm.nih.gov/30367120/
2. Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003). Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. *The American Journal of Surgical Pathology*, 27(5), 612-624. https://pubmed.ncbi.nlm.nih.gov/12717169/
3. Wang, C., Yin, J., Li, X., Wu, X., & Liu, C. (2020). Immune checkpoint inhibitors in renal cell carcinoma: Mechanisms, clinical trials, and future perspectives. *Journal for Immunotherapy of Cancer*, 8(1), e000570. https://pubmed.ncbi.nlm.nih.gov/32238466/

7. T Cell Subset Population Analysis in Kidney Normal and Tumor Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of T cell and related innate lymphoid cell (ILC) subsets, as defined by celltype_subset, across individual normal and tumor kidney samples. The primary goal is to identify differences in the immune cell composition within the T cell compartment between healthy kidney tissue and renal cell carcinoma (tumor tissue).

Visual Summary

The stacked bar plot shows the distribution of various T cell subsets (including ILCs and NK cells) for each sample, grouped by 'normal' and 'tumor' conditions. Each bar represents 100% of the T cell major population for a given sample, with different colors indicating specific subsets.

• Overall Dominance: In both normal and tumor conditions, T cell (Cytotoxic) appears to be a consistently dominant population, forming a substantial proportion of the T cell compartment in most samples.

Normal Samples:

• Normal samples (e.g., SI_22369, SI_22605) show a diverse distribution of T cell subsets, including appreciable proportions of NK cell, T cell (Naive), T cell (Tfh), T cell (Th1), T cell (Th17), T cell (Treg), and various ILCs.
• T cell (Cytotoxic) still constitutes a large fraction, often exceeding 50% in many normal samples.
• T cell (Treg) (dark blue) and unassigned (darker blue) are present in varying but generally smaller proportions.
• ILCs (ILC1, ILC2, ILC3 (NCR-), ILCreg, LTI – burgundy to orange) are present in some normal samples, with samples like SI_22369 and SI_22605 showing more prominent ILC populations than others (e.g., SI_18856, SI_21256).

Tumor Samples:

• The tumor samples generally exhibit a similar pattern of T cell (Cytotoxic) dominance.
• There appears to be an increased presence of T cell (Treg) (dark blue) in several tumor samples (e.g., SI_22368, SI_23843, SI_21561, SI_22604) compared to most normal samples.
• The proportion of NK cell (light orange) seems to vary significantly between tumor samples.
• T cell (Naive) (light yellow) appears to be present in both conditions, but its proportion may vary.
• Helper T cell subsets (T cell (Th1), T cell (Th17), etc.) show variable presence across tumor samples, with no single consistent enrichment or depletion immediately obvious across all tumor samples compared to normal.
• ILC populations (red to orange spectrum) are also present in tumor samples, with some variability.
• Variability between Samples: Both normal and tumor groups show inter-sample variability in T cell subset composition, highlighting potential patient-specific immune responses or differences in tissue microenvironment. For instance, SI_21256 (normal) is almost entirely T cell (Cytotoxic) with very few other subsets, which is an outlier compared to other normal samples.

Biological Interpretation

The observed shifts in T cell subset populations provide insights into the immune landscape of renal cell carcinoma.

• Dominance of Cytotoxic T cells: The high proportion of T cell (Cytotoxic) in both normal kidney tissue and tumors is expected, as CD8+ cytotoxic T cells are crucial for eliminating virally infected cells and cancer cells. Their presence in tumors suggests an attempt by the immune system to control tumor growth, although their functional state (e.g., exhausted) is not indicated by population size alone.
• Enrichment of Regulatory T cells (Tregs) in Tumors: The apparent increase in T cell (Treg) in several tumor samples is a significant finding. Tregs are known to suppress anti-tumor immune responses, creating an immunosuppressive tumor microenvironment that favors tumor growth and evasion from immune surveillance. Their enrichment is a common feature in many cancers, including kidney cancer, and can be a barrier to effective immunotherapy [1, 2].
• Variability of NK Cells: NK cells are critical innate immune cells with direct cytotoxic activity against tumor cells. The variability in NK cell proportions in tumor samples could reflect different stages of immune infiltration or diverse immune evasion strategies employed by individual tumors.
• Helper T Cell Subsets: The presence of various helper T cell subsets (Th1, Th2, Th9, Th17, Th22, Tfh) indicates a complex adaptive immune response.
• T cell (Th1) typically supports anti-tumor immunity via IFN-γ production.
• T cell (Th17) can have context-dependent roles, either pro-inflammatory and anti-tumor or tumor-promoting.
• T cell (Th2) responses are generally associated with allergic reactions and can sometimes promote tumor growth by fostering an immunosuppressive environment.
• Changes in the balance of these subsets could dictate the overall nature of the adaptive immune response within the kidney tumor microenvironment.
• Innate Lymphoid Cells (ILCs): The presence of ILCs (ILC1, ILC2, ILC3, ILCreg, LTI) in both normal and tumor samples highlights their role in kidney immunity. ILCs act as early responders, mirroring the functions of T helper cells without antigen specificity. Their specific contribution to renal cancer progression or control is an active area of research. For instance, ILC1s may contribute to anti-tumor immunity, while ILC2s have been implicated in both pro- and anti-tumor contexts [3].

Clinical or Translational Implications

The findings from this T cell subset population analysis have several potential clinical implications for kidney cancer:

• Immunosuppressive Microenvironment: The consistent presence and potential enrichment of T cell (Treg) in tumor samples suggest an immunosuppressive tumor microenvironment. This could explain resistance to certain immunotherapies that rely on robust effector T cell function. Strategies targeting Tregs, such as depletion or inhibition, might be explored to enhance the efficacy of existing immunotherapies [2].
• Biomarker Potential: The specific proportions of T cell subsets (e.g., Treg/Cytotoxic T cell ratio, NK cell abundance) could serve as prognostic biomarkers, predicting patient outcomes or response to therapy. Patients with a higher proportion of Tregs in their tumors might have a poorer prognosis.
• Therapeutic Targets: Understanding the precise balance of helper T cell subsets and ILCs in renal tumors could inform the development of novel immunotherapies. For example, enhancing Th1 or ILC1 responses, or modulating Th17 or Th2 responses, could re-educate the immune system to better combat the tumor.
• Patient Heterogeneity: The significant sample-to-sample variability observed underscores the importance of personalized medicine approaches. Immune profiling of individual patients could help tailor treatment strategies based on their unique tumor immune microenvironment.

---

References

1. Wing, K., & Sakaguchi, S. (2010). Regulatory T cells exert checks and balances on the immune system. *Nature Immunology*, 11(11), 1013-1021. PubMed Search: regulatory T cells cancer immunosuppression
2. Zou, W. (2005). Regulatory T cells, tumor immunity and immunotherapy. *Nature Reviews Immunology*, 5(4), 262-272. PubMed Search: regulatory T cells tumor immunity immunotherapy
3. Vivier, E., Artis, D., Colonna, S. M., Diefenbach, M. M., Di Santo, J. P., Eberl, G., ... & Spits, H. (2018). Innate Lymphoid Cells: 10 Years On. *Cell*, 174(5), 1054-1061. PubMed Search: Innate Lymphoid Cells cancer

8. Differential Proportion of Regulatory T Cells (Tregs) in Kidney Tumor vs. Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportion of T cell subset populations, specifically Regulatory T cells (Tregs), in kidney tissue, comparing tumor conditions against normal tissue. A boxplot visualization was generated to highlight statistically significant differences in Treg cell proportions between these two conditions, with the normal group serving as the reference.

Visual Summary

The boxplot clearly illustrates the proportion of Treg cells in 'tumor' versus 'normal' kidney tissue samples.

• In the 'tumor' condition, the median Treg cell proportion appears substantially higher than in the 'normal' condition. The box for 'tumor' extends over a wider range, indicating greater variability, with individual data points (stripplot) showing proportions from near 0% up to approximately 17%.
• In contrast, the 'normal' condition exhibits a lower median Treg proportion, with most individual data points falling below 5% and a narrower interquartile range.
• A p-value of 0.10 is indicated above the plot, suggesting a statistically significant trend, reaching the predefined cutoff, where Treg cell proportion tends to be higher in kidney tumor samples compared to normal tissue.

Biological Interpretation

Regulatory T cells (Tregs) are a specialized subset of T lymphocytes (T cells) crucial for maintaining immune homeostasis and preventing autoimmunity through their potent immunosuppressive functions 1. Their role in the tumor microenvironment (TME) is well-established across various cancer types.

The observed trend of increased Treg cell proportion in kidney tumor tissue (p=0.10) strongly suggests an active immunosuppressive state within the tumor. This elevation of Tregs in the TME typically leads to:

• Suppression of Anti-tumor Immunity: Tregs inhibit the proliferation and function of effector T cells (such as cytotoxic CD8+ T cells and helper CD4+ T cells), natural killer (NK) cells, and antigen-presenting cells. This suppression cripples the host's ability to mount an effective immune response against the cancer cells 2.
• Promotion of Tumor Growth and Progression: By dampening immune surveillance, Tregs create an "immune-privileged" environment that allows tumor cells to evade destruction, proliferate unchecked, and potentially metastasize.
• Disease Context: In kidney cancer, specifically renal cell carcinoma (RCC), the accumulation of Tregs is a recognized mechanism of immune escape and is often associated with advanced disease and poorer prognosis. The current data aligns with this understanding, indicating an enrichment of immunosuppressive cells in the diseased tissue.

Clinical or Translational Implications

The finding of elevated Treg proportions in kidney tumors has significant clinical and translational implications:

• Prognostic Marker: An increased Treg infiltration in kidney tumors could serve as a potential prognostic biomarker, with higher levels possibly correlating with poorer outcomes due to enhanced immune evasion.
• Therapeutic Target: Given their immunosuppressive role, Tregs represent an attractive target for cancer immunotherapy. Strategies aimed at depleting Tregs, inhibiting their function, or converting them into effector T cells could potentially unleash anti-tumor immunity and improve the efficacy of existing treatments, such as immune checkpoint blockade 3.
• Patient Stratification: The variability in Treg proportions among tumor samples suggests that patients might differ in their degree of immune suppression. This could be a factor in stratifying patients for specific immunotherapy regimens or predicting their response. Further research into this variability could lead to personalized treatment approaches.

9. Macrophage Subset Population Analysis in Normal and Tumor Kidney Tissues

[Analysis Visualization Results]...

Analysis Overview

This analysis presents the proportional distribution of various macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual samples from both normal and tumor kidney tissues. The goal is to identify potential shifts in macrophage polarization in the tumor microenvironment compared to normal tissue, which can provide insights into disease biology and immune response.

Visual Summary

The stacked bar plot visualizes the relative proportions of five macrophage subsets (M1, M2A, M2B, M2C, M2D) for each sample, separated by "normal" and "tumor" conditions.

• Normal Samples: The normal kidney samples exhibit a diverse macrophage landscape. Macrophage (M1) and Macrophage (M2A) populations are generally prominent, with their relative proportions varying among samples. Macrophage (M2B) is also present, while Macrophage (M2C) and Macrophage (M2D) appear in minimal proportions. Notably, in some normal samples (e.g., SI_18856, SI_22605, SI_22369), M2A macrophages constitute a significant fraction, sometimes exceeding M1.
• Tumor Samples: In contrast, the tumor kidney samples show a striking enrichment of Macrophage (M1) cells, which represent the dominant subset in most tumor samples, often accounting for over 60% of the total macrophage population. While Macrophage (M2A), Macrophage (M2B), and Macrophage (M2C) are still present, their individual contributions are generally lower compared to M1 in the tumor context. Macrophage (M2D) remains at very low levels, similar to normal samples.
• Comparison between Conditions: The most prominent difference is the marked increase in the relative abundance of Macrophage (M1) in tumor samples compared to normal samples. Conversely, Macrophage (M2A) populations, which were substantial in some normal samples, appear relatively reduced in proportion across many tumor samples.

Biological Interpretation

Macrophages are critical components of the immune system and play multifaceted roles in cancer, often polarizing into different functional subsets in response to microenvironmental cues. The classical M1/M2 paradigm describes M1 macrophages as pro-inflammatory and tumoricidal, while M2 macrophages are often associated with immune suppression, angiogenesis, and tissue repair, generally supporting tumor growth. However, this is a simplification, and macrophages exhibit high plasticity and diverse functions within the tumor microenvironment (TME) [1].

• Dominance of M1 Macrophages in Kidney Tumors: The observed substantial prevalence of M1 macrophages in kidney tumor samples is a significant finding. M1 macrophages are typically characterized by their ability to present antigens, produce pro-inflammatory cytokines (e.g., TNF-α, IL-1β), and exert direct cytotoxic effects on tumor cells. Their strong presence might indicate an ongoing, potentially effective, anti-tumor immune response within these kidney tumors. This could be reflective of specific intrinsic properties of kidney cancer, or a particular stage or subtype of the disease.
• Shift from M2A to M1 Polarization: The relative decrease of M2A macrophages and the increase of M1 macrophages in the tumor compared to some normal samples suggest a shift in macrophage polarization within the TME. While M2A macrophages are generally involved in allergic responses and parasitic infections, their presence in normal tissue might reflect baseline homeostatic immune functions. Their reduction, alongside M1 enrichment in tumors, could imply an active immune reprogramming event orchestrated by the tumor or host immune response.
• Implications for Tumor Microenvironment: The high proportion of M1 macrophages, generally considered anti-tumorigenic, in the TME requires further functional characterization. It raises questions about whether these M1 cells fully retain their cytotoxic function in the tumor context or if they represent a state influenced by other suppressive mechanisms. Nevertheless, their numerical dominance suggests a potential "hot" or immune-inflamed tumor phenotype, which is often associated with better responses to certain immunotherapies [2].

Clinical or Translational Implications

• Prognostic Value: The relative abundance of M1 macrophages versus other M2 subsets could serve as a valuable prognostic biomarker in kidney cancer. A higher M1:M2 ratio might correlate with better clinical outcomes, provided these M1 cells are functionally competent.
• Therapeutic Stratification and Targets: Understanding the drivers of M1 polarization in kidney tumors could pave the way for novel therapeutic strategies. For instance, therapies aimed at enhancing M1 macrophage activation or preventing their conversion to more pro-tumorigenic M2 phenotypes could augment anti-tumor immunity. The observed M1 dominance might also help stratify patients who are more likely to respond to immunotherapies that rely on a pre-existing anti-tumor immune response, such as immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockade) [2].
• Heterogeneity of Immune Response: The sample-to-sample variability in macrophage subset distribution underscores the high heterogeneity of the immune response in kidney cancer patients. This highlights the need for personalized approaches to cancer treatment, where the immune landscape of each patient's tumor can guide therapeutic decisions.

---

References:

1. Macrophage Polarization and Function in Cancer: Review articles on this topic can be found by searching "macrophage polarization cancer review" on PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+polarization+cancer+review
2. Tumor-associated macrophages and immunotherapy: For information on the role of TAMs in immunotherapy response, search "tumor associated macrophages immunotherapy review" on PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=tumor+associated+macrophages+immunotherapy+review

10. Ploidy Population Analysis of Tumor Origin and Unassigned Cells in Kidney Samples

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of cells identified as 'Renal Epithelial cell' (the presumed tumor origin cell type) and 'unassigned' cells across various normal and tumor kidney samples. Ploidy, which refers to the number of sets of chromosomes in a cell, is a critical feature, as aneuploidy (an abnormal number of chromosomes) is a hallmark of many cancers, including renal cell carcinoma. The bar plot visualizes the proportional distribution of these ploidy states for each sample within the specified cell populations.

Visual Summary

The stacked bar plots display the relative proportions of Aneuploid (dark red), Diploid (orange), and Unclear (light green) cells for each sample, separated by 'normal' and 'tumor' conditions.

• Normal Samples: Most normal samples (e.g., SI_18856, SI_19704, SI_21256) are predominantly composed of Diploid cells, with aneuploid cells making up a very small fraction or being entirely absent. However, some normal samples (e.g., SI_22369, SI_22605, SI_21255) show a significant proportion, or even a majority, of Aneuploid cells. A small fraction of cells are categorized as 'Unclear' in most normal samples.
• Tumor Samples: In stark contrast, the vast majority of tumor samples (e.g., SI_22368, SI_23843, SI_19703, SI_18854, SI_23459, SI_21561, SI_22604) are overwhelmingly dominated by Aneuploid cells, often comprising over 90-95% of the population. A few tumor samples (e.g., SI_18855, SI_22368) still show a noticeable proportion of Diploid cells, but the trend towards high aneuploidy is consistent across almost all tumor samples. 'Unclear' cells are present in small proportions, similar to normal samples.

Biological Interpretation

The observed ploidy patterns strongly align with the expected genomic instability associated with renal cell carcinoma.

• Aneuploidy as a Cancer Hallmark: The dramatic shift from predominantly diploid cells in most normal kidney samples to overwhelmingly aneuploid cells in tumor samples provides strong evidence that the selected 'Renal Epithelial cell' population in tumor conditions represents the malignant cancer cells. Aneuploidy is a well-established characteristic of tumor cells, reflecting chromosomal instability that drives tumor evolution and heterogeneity [1].
• Heterogeneity in Normal Samples: The presence of a substantial fraction of aneuploid cells in some samples labeled as 'normal' (e.g., SI_22369, SI_22605, SI_21255) is an interesting observation. This could indicate several possibilities:
• Pre-neoplastic changes: These 'normal' samples might be adjacent to tumor tissue or harbor early, undetected neoplastic lesions that have already begun to accumulate chromosomal abnormalities.
• Field cancerization: A phenomenon where morphologically normal tissue surrounding a tumor has genetic alterations.
• Technical artifacts: While less likely given the clear trend in tumor samples, it's a consideration.
• Biological variability: Certain normal kidney cell types might naturally exhibit some degree of polyploidy or aneuploidy, though typically not to the extent seen in these samples.
• Tumor Purity and Clonal Evolution: The high proportion of aneuploid cells in tumor samples suggests a significant purity of tumor cells within the analyzed population or a strong clonal expansion of aneuploid cells. The variability in the small diploid fraction in some tumor samples (e.g., SI_18855, SI_22368) could represent infiltrating normal stromal or immune cells that were inadvertently included in the 'Renal Epithelial cell' or 'unassigned' populations, or genuinely diploid tumor subclones.
• Role of 'Unassigned' Cells: Since both 'Renal Epithelial cell' and 'unassigned' populations were selected, the observed patterns are a composite. Given that 'Renal Epithelial cell' is the designated tumor origin, it's highly probable that the aneuploid signal is predominantly driven by these malignant epithelial cells. If 'unassigned' cells in tumor samples also show high aneuploidy, it might suggest that some of these 'unassigned' cells are indeed misclassified tumor cells or highly perturbed cells within the tumor microenvironment.

Clinical or Translational Implications

The clear distinction in ploidy between most normal and tumor samples has significant implications for diagnosis and understanding tumor biology in kidney cancer.

• Diagnostic Biomarker: The high prevalence of aneuploidy in renal tumor cells could serve as a valuable diagnostic or prognostic marker, particularly when assessed in specific cell populations identified as potentially malignant.
• Therapeutic Targeting: Aneuploidy often leads to cellular stress and dependence on specific compensatory pathways (e.g., those involved in cell cycle control, DNA repair, or proteostasis). Targeting these vulnerabilities, which are often amplified in aneuploid cells, is an active area of cancer research [2].
• Monitoring Tumor Evolution: Tracking ploidy changes over time could provide insights into tumor progression or response to therapy. The presence of aneuploid cells in ostensibly "normal" tissue highlights the challenges in defining tumor margins and may suggest areas of high recurrence risk.
• Refining Cell Type Classification: The samples showing high aneuploidy in the "normal" condition warrant further investigation. It is crucial to determine if these are indeed normal cells with unique ploidy features, early neoplastic lesions, or misclassified samples, as this could impact the interpretation of other analyses (e.g., DEG, GSEA).

References

1. Aneuploidy as a hallmark of cancer:

• PubMed Search: "aneuploidy cancer hallmark" https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+hallmark

2. Therapeutic targeting of aneuploidy:

• PubMed Search: "aneuploidy cancer therapy" https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+therapy

11. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns using single-cell RNA-seq data from human kidney tissue, comparing normal and tumor samples. The focus is on interactions involving Renal Epithelial cells (as tumor origin cells), Fibroblasts, Macrophages, and T cells, with the tool selecting up to 80 most significant interactions per condition based on p-value. The resulting dot plot visualizes the standardized mean expression of ligand-receptor pairs and the significance (-log10(p-value)) of these interactions across individual samples for both normal and tumor conditions.

Visual Summary

The visualization clearly demonstrates a profound difference in cell-cell interaction profiles between normal and tumor kidney samples.

• Striking Upregulation in Tumor: The most prominent feature is the dramatic increase in the intensity (redder color, indicating higher standardized mean interaction strength) and significance (larger dot size, indicating lower p-values) of cell-cell interactions in the tumor condition compared to normal. Normal samples generally show sparse, pale, and small dots, suggesting limited or less significant interactions. In contrast, tumor samples exhibit numerous large, dark red dots across a wide array of ligand-receptor pairs.
• Dominant Cell Types in Tumor Interactions: The majority of the highly active interactions in the tumor samples primarily involve Renal Epithelial cells (Renal.Epi, often noted with ploidy status, e.g., (Dip) for Diploid or (Aneup) for Aneuploid), Endothelial cells (Endo), Macrophages (Mac), and Smooth Muscle Cells (SMC). While Fibroblasts and T cells were target cells in the query, they are not prominently represented in the top 80 interactions shown on this plot.

Key Interaction Categories in Tumor

• Extracellular Matrix (ECM) & Adhesion: A large number of upregulated interactions involve various integrin complexes (e.g., FN1-integrin, COL4A1-integrin, COL18A1-integrin, COL15A1-integrin, COL6A1-integrin) primarily between Renal Epithelial cells and Endothelial cells.
• Growth Factor Signaling: VEGFA_FLT1, VEGFA_NRP1, and PGF_NRP1 interactions, predominantly between Renal Epithelial cells and Endothelial cells, are highly active in tumors.
• NOTCH Signaling: JAG1_NOTCH1, JAG1_NOTCH2, JAG1_NOTCH3, and JAG2_NOTCH2 interactions, often between Renal Epithelial and Endothelial cells, are also markedly increased.
• Immune Modulation: Interactions involving Macrophages are prominent, notably SIRPA_CD47--Mac|Renal.Epi(Dip) and PLAU_PLAUR--Mac|Renal.Epi(Dip). CXCL12_CXCR4--Endo|Mac and IL6_IL6_receptor--Endo|Mac also show strong activity.
• Ploidy Specificity: Interactions involving Renal.Epi(Aneup) (Aneuploid Renal Epithelial cells) are also present and active in the tumor microenvironment (e.g., FN1_integrin_a1b1_complex--Renal.Epi(Aneup)|Endo), suggesting distinct or amplified roles for aneuploid tumor cells in mediating these communications.

Biological Interpretation

The observed shifts in cell-cell interaction patterns provide critical insights into the biological processes driving kidney tumor progression.

1. Enhanced Angiogenesis: The robust upregulation of VEGFA_FLT1, VEGFA_NRP1, and PGF_NRP1 signaling from Renal Epithelial cells to Endothelial cells is a hallmark of active tumor angiogenesis. This process is crucial for supplying oxygen and nutrients to the rapidly growing tumor and facilitating metastasis. GeneCards: VEGFA
2. Immune Evasion and Remodeling: The prominent SIRPA_CD47 interaction between tumor Renal Epithelial cells and Macrophages suggests a key mechanism for immune evasion. CD47 on cancer cells acts as a "don't eat me" signal, binding to SIRPA on macrophages to inhibit phagocytosis. The PLAU_PLAUR interaction involving macrophages and tumor cells indicates potential for extracellular matrix degradation, contributing to both immune cell infiltration and tumor invasion. The activation of CXCL12_CXCR4 and IL6_IL6_receptor between Endothelial cells and Macrophages points to a pro-inflammatory and pro-tumorigenic microenvironment, influencing immune cell recruitment and tumor growth. PubMed Search: CD47 SIRPA cancer immunotherapy
3. Tumor Microenvironment (TME) Plasticity and Invasion: The extensive involvement of various integrin complexes in interactions between Renal Epithelial cells and Endothelial/Smooth Muscle cells underscores significant remodeling of the TME. Integrins are essential for cell adhesion, migration, and invasion, processes critical for tumor growth and metastatic spread. Upregulated NOTCH signaling in the tumor further contributes to TME plasticity, influencing cell fate, stemness, and potentially tumor cell proliferation and survival.
4. Role of Aneuploid Tumor Cells: The specific engagement of Renal.Epi(Aneup) cells in certain highly active interactions indicates that these genetically unstable tumor cells contribute uniquely or more aggressively to specific intercellular communications that may foster tumor characteristics like invasion and angiogenesis. This highlights the functional implications of tumor heterogeneity.

Clinical or Translational Implications

The distinct and highly active cell-cell interactions in the kidney tumor microenvironment represent promising avenues for therapeutic intervention and biomarker discovery.

1. Targeted Therapies:

• Anti-angiogenic strategies: The strong VEGFA/PGF-FLT1/NRP1 signaling axis reinforces the rationale for existing anti-angiogenic therapies and suggests potential for combination therapies targeting these pathways in kidney cancer.
• Immune checkpoint blockade: Inhibiting the SIRPA-CD47 "don't eat me" signal offers a compelling immunotherapeutic strategy to unleash macrophage-mediated anti-tumor immunity.
• ECM and NOTCH Pathway Inhibition: Modulating specific integrin interactions or NOTCH signaling pathways could disrupt tumor cell adhesion, migration, and self-renewal, potentially reducing metastasis and recurrence.

2. Biomarker Development: The identified highly activated ligand-receptor pairs could serve as prognostic biomarkers, indicating disease aggressiveness, or predictive biomarkers, helping to stratify patients for response to specific targeted therapies.
3. Understanding Therapeutic Resistance: The complex interplay of cell types and signaling pathways within the TME, particularly those involving aneuploid tumor cells, may contribute to therapeutic resistance. A deeper understanding of these interactions could inform strategies to overcome resistance mechanisms.

12. Cell-Cell Interaction Analysis by Condition in Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) within kidney tissue, comparing a 'normal' condition against a 'tumor' condition. Using CellPhoneDB, ligand-receptor interactions were identified and visualized, highlighting the most significant and highly expressed interactions for each condition. The results provide insights into the communication networks that define normal kidney homeostasis versus the disrupted and pro-tumorigenic microenvironment in kidney cancer.

Visual Summary

The dot plots illustrate cell-cell interactions by condition, with dot size representing the statistical significance (-log10(p-value)) and dot color indicating the mean expression level of the ligand-receptor pair (log2(mean)). A maximum of 80 significant interactions are shown for each condition.

CCI in Normal Kidney Tissue

In the 'normal' condition, cell-cell interactions are predominantly observed between:

Endothelial cells (Endo) and Endothelial cells (Endo)

• Diploid Renal Epithelial cells (Diploid Renal Epi) and Endothelial cells (Endo)
• Diploid Renal Epithelial cells (Diploid Renal Epi) and themselves.

Key ligand-receptor pairs prominent in normal tissue include:

• Cell Adhesion and ECM: CDH1-integrin (E-cadherin with integrins), various COL-integrin (collagen with integrins), FN1-integrin (fibronectin with integrins). These interactions are fundamental for maintaining tissue structure and epithelial integrity.
• Angiogenesis and Vasculature: VEGFA-FLT1/KDR (VEGFA with its receptors) and EDN1-EDNRA/B (Endothelin-1 with its receptors) highlight normal vascular regulation.
• Developmental and Growth Signaling: JAG1-NOTCH3/4 (Jagged1 with Notch receptors) and EPHA/B families are involved in cell fate, angiogenesis, and tissue patterning.
• Immune/Inflammatory Modulation: CCL5-CCR5, CCL2-CCR2, CXCL12-CXCR4 suggest baseline immune surveillance and chemokine-mediated communication.

These interactions largely reflect processes crucial for maintaining healthy kidney tissue architecture, vascular function, and homeostatic epithelial-stromal cross-talk.

CCI in Tumor Kidney Tissue

In the 'tumor' condition, there is a striking shift in the interacting cell populations and the nature of the ligand-receptor pairs. Dominant interactions are observed between:

Smooth Muscle Cells (SMC) and Smooth Muscle Cells (SMC)

Smooth Muscle Cells (SMC) and Macrophages (Mac)

Macrophages (Mac) and Macrophages (Mac)

• Macrophages (Mac) and Aneuploid Renal Epithelial cells (Aneuploid Renal Epi)
• Aneuploid Renal Epithelial cells (Aneuploid Renal Epi) and Macrophages (Mac)
• Aneuploid Renal Epithelial cells (Aneuploid Renal Epi) and themselves.

The "Aneuploid Renal Epi" cells, given the ploidy_dec annotation and the context of 'tumor origin celltype', represent the malignant renal epithelial cells.

Key ligand-receptor pairs prominent in tumor tissue include:

Immune Evasion and Suppression:

• CD47-SIRPA ("don't eat me" signal), APOE-TREM2 (associated with tumor-associated macrophages, TAMs), CD200-CD200R1 (immune checkpoint), IL10-IL10RA/RB (immunosuppressive cytokine), ADORA3-ENTPD1 (adenosine pathway). These pathways are critically involved in tumor cells evading immune surveillance and in reprogramming macrophages to a pro-tumorigenic phenotype.
• Growth Factors and Angiogenesis: HBEGF-EGFR (EGFR signaling is a known oncogenic driver), PDGFB-PDGFRB (involved in angiogenesis and stromal remodeling), and VEGFA-FLT1/KDR/NRP1/2 (angiogenesis).
• ECM Remodeling and Invasion: A broader array of integrin interactions with various collagens (COL4A1/2-integrin, COL6A1-integrin), fibronectin (FN1-integrin), and other ECM components (CSPG4-integrin, LAMC1-integrin, SPP1-CD44, THBS1-integrin). This points to extensive and dysregulated extracellular matrix remodeling characteristic of tumor invasion and metastasis.
• Chemokine Signaling: Various CCL-CCR and CXCL-CXCR interactions (e.g., CCL2-CCR2, CCL3-CCR1, CCL4-CCR1, CCL5-CCR5) highlight continuous recruitment of immune cells to the tumor microenvironment.
• Other oncogenic pathways: DLK1-NOTCH1/2 (Notch signaling) and LGALS1-CD44 (Galectin-1 pathway).

Biological Interpretation

Condition-Specific Cell-Cell Interaction Landscapes

The analysis reveals a profound reorganization of cell-cell communication networks in kidney tumor tissue compared to normal. Normal kidney tissue interactions are dominated by epithelial-endothelial cross-talk and self-interactions, reflecting stable tissue architecture and homeostatic regulation. In contrast, the tumor microenvironment (TME) is characterized by extensive interactions involving macrophages and malignant (Aneuploid Renal Epithelial) cells, alongside smooth muscle cells. This shift underscores the critical role of immune infiltration, particularly macrophages, and altered stromal components in shaping the tumor landscape.

Key Pathways in Normal Tissue Homeostasis

In normal kidney, interactions like CDH1-integrin and FN1-integrin highlight the importance of epithelial cell-cell adhesion and epithelial-extracellular matrix (ECM) interactions for tissue integrity. The presence of EDN1-EDNRA/B and VEGFA-FLT1/KDR suggests active regulation of vascular tone and angiogenesis, vital for kidney function. The baseline chemokine interactions (e.g., CCL5-CCR5) likely represent physiological immune surveillance.

Oncogenic and Immunosuppressive Pathways in Tumor Microenvironment

The tumor condition exhibits a striking upregulation of interactions associated with cancer progression:

• Immune Evasion: The strong presence of CD47-SIRPA, CD200-CD200R1, IL10-IL10RA/RB, and ADORA3-ENTPD1 pathways points towards active mechanisms by tumor cells to evade immune destruction and promote an immunosuppressive TME. CD47-SIRPA, for instance, is a well-known "don't eat me" signal that cancer cells use to inhibit phagocytosis by macrophages [1].
• Macrophage Reprogramming: Interactions like APOE-TREM2 and numerous macrophage-tumor cell CCIs suggest that macrophages are actively recruited and reprogrammed within the TME to support tumor growth rather than eliminate it. These tumor-associated macrophages (TAMs) often contribute to immunosuppression, angiogenesis, and metastasis [2].
• Growth and Proliferation: The activation of growth factor signaling (HBEGF-EGFR, PDGFB-PDGFRB) is critical for uncontrolled tumor cell proliferation and survival. EGFR signaling is a prominent oncogenic pathway in many cancers, including kidney cancer [3].
• Angiogenesis: Robust VEGFA-receptor interactions, along with PDGFB, signify enhanced angiogenesis, which is essential for nutrient supply and waste removal in rapidly growing tumors.

Altered Extracellular Matrix Interactions

The diverse array of integrin-ECM interactions (collagen, fibronectin, CSPG4, laminin) in tumor tissue highlights significant remodeling of the ECM. This dynamic remodeling is not just a consequence but an active contributor to tumor invasion, metastasis, and altered mechanosignaling, facilitating cancer progression [4].

Clinical or Translational Implications

Therapeutic Target Prioritization

The identified tumor-specific and highly active CCIs offer promising avenues for therapeutic intervention in kidney cancer:

• Immune Checkpoint Blockade: The prominence of CD47-SIRPA and CD200-CD200R1 in the tumor context strongly suggests that targeting these pathways could disrupt immune evasion, allowing the host immune system to better attack tumor cells. Antibodies against CD47 are currently in clinical trials for various cancers [1].
• TAM Reprogramming: Pathways such as APOE-TREM2, IL10-IL10RA/RB, and ADORA3-ENTPD1, which are active in macrophage-tumor interactions, represent potential targets to reprogram pro-tumorigenic macrophages into anti-tumorigenic states.
• Growth Factor Receptor Inhibition: HBEGF-EGFR and PDGFB-PDGFRB signaling are well-established targets in oncology. Inhibitors against these pathways could block crucial proliferation and survival signals for tumor cells and associated stromal cells [3].
• Anti-angiogenic Therapy: VEGFA-receptor and PDGFB-PDGFRB interactions reinforce the rationale for anti-angiogenic therapies, which aim to starve tumors by inhibiting new blood vessel formation.
• ECM-targeting Strategies: While more complex, selectively targeting specific integrin-ECM interactions that are highly prevalent in tumors could potentially inhibit invasion and metastasis [4].

Biomarker Potential

Specific ligand-receptor pairs or patterns of CCI unique to the tumor condition could serve as diagnostic or prognostic biomarkers. For instance, high expression or activity of certain immune checkpoint pathways or ECM remodeling markers might indicate aggressive disease or predict response to specific therapies.

Experimental Validation Strategies

The identified CCIs warrant further experimental validation. This could involve:

• _In vitro_ functional assays: Co-culture experiments using renal epithelial cancer cell lines and macrophages, or endothelial cells, to test the functional impact of disrupting these ligand-receptor interactions on cell proliferation, migration, invasion, and immune cell polarization.
• _In vivo_ models: Using genetically engineered mouse models or patient-derived xenografts to validate the therapeutic efficacy of targeting these pathways, alone or in combination, on tumor growth, metastasis, and immune modulation.
• Spatial transcriptomics: Further investigation with spatial methods could precisely localize these interactions within the tumor microenvironment and confirm their physical proximity.

---

References:

1. CD47-SIRPA immune checkpoint: PubMed Search: CD47 SIRPA cancer immunotherapy
2. TREM2 and tumor-associated macrophages: PubMed Search: TREM2 tumor associated macrophages
3. EGFR signaling in kidney cancer: PubMed Search: EGFR signaling kidney cancer
4. Integrins and ECM in tumor invasion: PubMed Search: Integrin ECM tumor invasion

13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Pathways in Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) using CellPhoneDB, focusing specifically on ligand-receptor pairs involving genes related to immune checkpoint and cell cycle pathways. The plot_cci_dots tool was used to visualize significant interactions (p-value < 0.05, mean expression > 0.01) within normal and tumor kidney tissue. The results highlight distinct communication patterns in healthy kidney compared to the tumor microenvironment, specifically identifying interactions between Endothelial cells and Diploid Renal Epithelial cells in normal tissue, and a prominent interaction between Macrophages and Aneuploid Renal Epithelial cells in tumor tissue.

Visual Summary

The visualization consists of two dot plots, one for "normal" and one for "tumor" conditions, showing significant cell-cell interactions based on expression of the specified immune checkpoint and cell cycle-related genes.

CCI for normal condition:

• This plot displays several active ligand-receptor interactions primarily involving Endothelial cells and Diploid Renal Epithelial cells.

Interactions are observed

• Within Endothelial cells (Endo|Endo).
• Between Endothelial cells and Diploid Renal Epithelial cells (Endo|Diploid Renal Epi).
• Within Diploid Renal Epithelial cells (Diploid Renal Epi|Diploid Renal Epi).
• Key ligand-receptor pairs identified include CD93_IFNGR1, EGF_EGFR, FGF1_FGFR3, TGFB1_TGFBR3, and TGFB1_integrin_aVb6_complex.
• All depicted interactions show high statistical significance (large dot sizes, indicating -log10(p) values close to or exceeding 10) and varying levels of mean expression (dot colors).

CCI for tumor condition:

• This plot shows a much more restricted set of interactions, with only one prominent interaction identified: Macrophage (Mac) interacting with Aneuploid Renal Epithelial cell (Aneuploid Renal Epi).
• The specific ligand-receptor pair mediating this interaction is HBEGF_EGFR.
• This interaction also demonstrates high statistical significance (large dot size, -log10(p) exceeding 10) and a high mean expression level (yellow dot color, log2(m) approx. 1.1).
• Notably, the Renal Epithelial cells in the tumor condition are characterized as "Aneuploid," indicating genomic instability typical of cancer cells, in contrast to "Diploid" cells in the normal condition.

Biological Interpretation

The analysis reveals a striking reprogramming of cell-cell communication pathways when comparing normal and tumor kidney tissue, particularly concerning components related to cell cycle and immune regulation.

1. Shifting Cellular Communication Landscape:

• In normal kidney, the observed interactions among Endothelial cells and Diploid Renal Epithelial cells via EGF_EGFR, FGF1_FGFR3, and TGFB1 pathways are consistent with their roles in maintaining tissue homeostasis, angiogenesis, and repair. These growth factor signaling pathways are fundamental for normal cell proliferation, differentiation, and survival GeneCards: EGFR, GeneCards: FGFR3, GeneCards: TGFB1. The presence of CD93_IFNGR1 interactions suggests a baseline immune regulatory activity important for tissue health.
• In tumor kidney, the communication network is drastically simplified and redirected. The sole prominent interaction identified is between Macrophages and Aneuploid Renal Epithelial cells via the HBEGF_EGFR axis. This highlights a critical, potentially tumor-promoting, interaction within the tumor microenvironment.

2. Role of Aneuploid Renal Epithelial Cells: The transition from Diploid to Aneuploid Renal Epithelial cells underscores the genomic instability and malignant transformation occurring in tumor tissue. These aneuploid cells, being the likely cancer cells, engage in distinct communication patterns compared to their normal counterparts.
3. Emergence of HBEGF-EGFR Axis in Tumor: The dominant HBEGF_EGFR interaction in tumor is highly significant. Heparin-binding EGF-like growth factor (HBEGF) is a potent mitogen and chemoattractant frequently overexpressed in various cancers, promoting tumor growth, invasion, and angiogenesis GeneCards: HBEGF. Macrophages, particularly tumor-associated macrophages (TAMs), are known to secrete growth factors that support cancer cell proliferation and survival. The macrophage-derived HBEGF activating EGFR on aneuploid renal epithelial cells suggests a direct pro-tumorigenic paracrine loop where TAMs foster the growth of renal cancer cells. This pathway also directly links to the requested 'cell cycle' related genes through EGFR signaling, which promotes cell cycle progression.

Clinical or Translational Implications

The observed shift in cell-cell interactions, particularly the prominence of the HBEGF-EGFR axis in the tumor context, offers several important clinical and translational insights:

1. Therapeutic Targeting of HBEGF-EGFR: The HBEGF-EGFR interaction represents a compelling therapeutic target in kidney cancer. Given that EGFR is a well-established oncogenic driver in many cancers, therapeutic strategies involving EGFR inhibitors (e.g., tyrosine kinase inhibitors) could be effective in disrupting this specific pro-tumorigenic communication between macrophages and cancer cells in renal tumors PubMed Search: EGFR inhibitors cancer therapy. Blocking HBEGF itself, or its interaction with EGFR, could potentially halt tumor progression driven by this pathway.
2. Macrophage Modulation in Kidney Cancer: The direct involvement of macrophages in this critical tumor-promoting interaction highlights the importance of tumor-associated macrophages (TAMs) in kidney cancer pathogenesis. Interventions aimed at depleting TAMs, reprogramming their pro-tumorigenic functions, or inhibiting their ability to secrete growth factors like HBEGF could be a valuable strategy to improve therapeutic outcomes PubMed Search: Tumor-associated macrophages cancer therapy.
3. Biomarker Development: The expression levels of HBEGF on macrophages and EGFR on aneuploid renal epithelial cells, as well as the activity of their interaction, could potentially serve as prognostic biomarkers for disease aggressiveness or predictive biomarkers for response to EGFR-targeted therapies.
4. Understanding Immune Evasion: While direct immune checkpoint ligand-receptor pairs were not prominently identified in this highly filtered view, the HBEGF-EGFR pathway has been implicated in creating an immunosuppressive microenvironment, for example, by influencing cytokine production or immune cell recruitment, which could indirectly contribute to immune evasion by kidney cancer cells. Further investigation into broader immune checkpoint interactions or cellular states influenced by this axis would be valuable.

14. Condition-Specific Cell-Cell Interaction Patterns in Kidney Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify statistically significant differences in cell-cell interactions (CCI) between normal kidney tissue and kidney tumor tissue, focusing on major immune and stromal cells. The plot_dot_for_cci_with_signif_difference tool was used to visualize these condition-specific interaction patterns, utilizing CellPhoneDB results. The dot plot displays interaction strength (color intensity) and statistical significance (-log10(p-value) as dot size) for various ligand-receptor pairs between defined cell types across individual samples, grouped by condition. The analysis specifically targeted interactions involving a broad range of immune and stromal cells including Macrophages, T cells, Smooth muscle cells, Dendritic cells, Mast cells, Plasma cells, Fibroblasts, B cells, NK cells, and ILCs, as well as endothelial and renal epithelial cells.

Visual Summary

The dot plot clearly segregates cell-cell interactions into two main groups based on condition: "normal" and "tumor."

• Normal-specific interactions (left panel, highlighted by a blue box): A distinct set of interactions shows strong activity (dark red, large dots) predominantly in normal kidney samples (e.g., SI_18856, SI_19704, SI_22605). These interactions appear largely absent or significantly weaker in tumor samples. Key interacting cell pairs in this group involve Macrophages and Renal Epithelial cells (both diploid and general), as well as Endothelial cells and Smooth Muscle Cells.
• Tumor-specific interactions (right panel, highlighted by a blue box): Conversely, a large cluster of interactions exhibits high activity (dark red, large dots) exclusively or predominantly in tumor samples (e.g., SI_18854, SI_19703, SI_23459). These interactions are largely diminished or absent in normal samples. This group features a wide array of interactions, notably numerous collagen-integrin interactions between Smooth Muscle Cells and Endothelial cells, as well as several Notch signaling components and immune checkpoint-related interactions.
• Interaction Strength and Significance: The color intensity (ranging from pale pink to dark red) represents the standardized mean of interaction strength, with darker reds indicating stronger interactions. The size of the dots corresponds to the -log10(p-value), where larger dots signify higher statistical significance for the observed interaction in that specific sample context. Both strong intensity and large size are prominent in the condition-specific clusters.

Biological Interpretation

Normal Kidney Homeostasis

The interactions enriched in normal kidney tissue appear to be critical for maintaining tissue homeostasis, immune tolerance, and epithelial integrity.

Immune Tolerance and Epithelial Maintenance:

• SIRPA-CD47 between Macrophages and Renal Epithelial cells: CD47, often referred to as a "don't eat me" signal, interacts with SIRPα on phagocytes like macrophages to inhibit phagocytosis. Its strong presence in normal tissue suggests a mechanism to protect healthy renal epithelial cells from immune surveillance and clearance by resident macrophages. PubMed Search: SIRPA CD47 kidney homeostasis
• EREG-EGFR and AREG-EGFR (Epiregulin/Amphiregulin-Epidermal Growth Factor Receptor) between Macrophages and Renal Epithelial cells: EGFR signaling is fundamental for epithelial cell proliferation, survival, and repair. These interactions likely contribute to the maintenance and regeneration of normal renal epithelium. GeneCards: EGFR
• PLAU-PLAUR (Urokinase-type plasminogen activator-receptor) between Macrophages and both other Macrophages and Renal Epithelial cells: This system is involved in pericellular proteolysis, cell migration, and tissue remodeling, crucial for homeostatic tissue turnover and inflammatory responses. PubMed Search: PLAU PLAUR kidney homeostasis

Vascular and Immune Regulation:

• EDN1-EDNRA (Endothelin-1-receptor A) between Endothelial and Smooth Muscle Cells: Endothelin-1 is a potent vasoconstrictor and plays a role in vascular tone regulation in normal kidney function.
• IL6-IL6_receptor between Macrophages and Renal Epithelial cells: Interleukin-6 is a pleiotropic cytokine with diverse roles in immunity and tissue repair, potentially regulating local inflammation and regenerative processes in a healthy kidney. GeneCards: IL6

Tumor Microenvironment Remodeling and Immune Dysregulation

In contrast, the interactions highly active in tumor samples point towards extensive extracellular matrix (ECM) remodeling, angiogenesis, and immune evasion mechanisms characteristic of the tumor microenvironment (TME).

Extensive ECM Remodeling and Angiogenesis:

• Numerous Collagen-Integrin Interactions: A striking feature is the abundance of interactions involving various collagen types (COL1A2, COL3A1, COL4A1, COL4A2, COL6A1, COL6A2, COL12A1, COL14A1, COL15A1, COL18A1) interacting with integrin_a10b1_complex or integrin_a1b1_complex on Smooth Muscle Cells and Endothelial Cells. Integrins mediate cell-matrix and cell-cell adhesion and signaling, which are critical for angiogenesis, cancer cell invasion, and the desmoplastic reaction often seen in kidney tumors. This indicates significant alterations in ECM composition and increased cell adhesion/migration, forming a supportive scaffold for tumor growth and spread. PubMed Search: Integrin collagen tumor microenvironment kidney

Pro-tumorigenic Signaling:

• Notch Signaling (DLL1/JAG2-NOTCH2/NOTCH3): Interactions involving Notch ligands (DLL1, JAG2) and receptors (NOTCH2, NOTCH3) are prominent between Endothelial cells and Smooth Muscle cells, as well as Endothelial cells and Macrophages. The Notch pathway is a key regulator of cell fate, differentiation, and tissue development. In the TME, it is frequently hijacked to promote angiogenesis, cancer stemness, and immune evasion, contributing to tumor progression. PubMed Search: Notch signaling kidney cancer angiogenesis

Immune Modulation and Suppression:

• RARR2-CCRL2 between Aneuploid Renal Epithelial cells (likely tumor cells) and Macrophages: RARR2 (also known as CMKLR1 or Chemerin Receptor 2) and CCRL2 are chemokine receptors. This interaction suggests chemokine signaling between tumor cells and macrophages, likely contributing to the recruitment and polarization of immune cells, potentially to an immunosuppressive phenotype within the TME.
• LAIR1-LILRB4 between Macrophages: LAIR1 (Leukocyte-associated immunoglobulin-like receptor 1) and LILRB4 (Leukocyte immunoglobulin-like receptor subfamily B member 4, also known as ILT3) are immune checkpoint molecules. LILRB4 on myeloid cells is known to inhibit T cell responses and promote M2 macrophage polarization, contributing to immune suppression in the TME. This interaction highlights an enhanced immunosuppressive axis within the macrophage population of the tumor. GeneCards: LILRB4
• TYROBP-CD44 between Macrophages: TYROBP (DAP12) is an adaptor protein crucial for immune cell activation and signaling. CD44 is a multi-functional cell surface glycoprotein involved in cell adhesion, migration, and immune cell activation. Their interaction could signify altered macrophage activation states or recruitment in the tumor.

Other Tumor-Associated Interactions:

• ThromboxaneA2_by_TBXAS1_TBXA2R between Macrophages and Endothelial cells: Thromboxane A2 is a potent lipid mediator involved in vasoconstriction, platelet aggregation, and inflammation. In cancer, it can promote angiogenesis, tumor growth, and metastasis.

Clinical or Translational Implications

The distinct condition-specific CCI patterns offer valuable insights for potential therapeutic interventions and biomarker discovery in kidney cancer.

Therapeutic Targeting of Tumor Microenvironment:

• ECM Remodeling: Inhibitors targeting specific collagen-integrin interactions could disrupt the tumor's supportive scaffold, inhibit angiogenesis, and impede cancer cell invasion. This approach could be explored as an adjunct to existing therapies.
• Notch Signaling Inhibition: Given the prominence of Notch signaling in tumor-associated angiogenesis and potentially cancer stemness, therapeutic agents that modulate Notch pathway components (e.g., gamma-secretase inhibitors) could be effective in disrupting the TME and slowing tumor progression.
• Immune Checkpoint Modulation: The identified LAIR1-LILRB4 axis on macrophages suggests a potential target for reversing immune suppression. Strategies to block LILRB4 or LAIR1, or to reprogram macrophages, could enhance anti-tumor immunity and improve responses to immunotherapy in kidney cancer patients. PubMed Search: LILRB4 cancer immunotherapy

Biomarker Discovery:

• The specific CCI pairs found to be highly active in tumor samples but absent in normal tissue could serve as novel diagnostic, prognostic, or predictive biomarkers for kidney cancer. For example, increased expression or activity of certain collagen-integrin axes or Notch pathway components detected in biopsies or liquid biopsies could indicate disease presence or progression.

15. 신장 상피세포의 조건별 표면 마커 분석

[Analysis Visualization Results]...

Analysis Overview

본 분석은 신장 상피세포(Renal Epithelial cell)에서 정상(normal) 및 종양(tumor) 조건에 따라 차등 발현되는 표면 마커 유전자들을 도트 플롯으로 시각화한 결과입니다. 이 분석은 단일 세포 RNA 시퀀싱(single-cell RNA-seq) 데이터를 기반으로 특정 조건(정상 또는 종양)에서 고유하게 발현되거나 과발현되는 표면 단백질 유전자들을 식별하여, 신장 상피세포의 조건별 특징을 이해하고 잠재적인 바이오마커 및 치료 표적을 발굴하는 데 초점을 맞춥니다.

Visual Summary

도트 플롯은 각 샘플(Diploid/정상, 정상, 종양) 및 해당 조건에 따른 신장 상피세포에서의 유전자 발현 패턴을 보여줍니다.

• 행(y-축): 다양한 환자 샘플(예: 'Diploid SI_18856', 'SI_22605')을 나타내며, 핵형(ploidy) 및 조건(정상/종양)에 따라 그룹화되어 있습니다. 오른쪽에 있는 막대는 각 샘플에 포함된 세포의 수를 나타냅니다.
• 열(x-축): 각 조건에서 선별된 상위 표면 마커 유전자들을 나타냅니다.
• 점의 크기: 해당 그룹 내에서 유전자를 발현하는 세포의 비율(Fraction of cells in group, %)을 나타냅니다. 점이 클수록 더 많은 세포가 유전자를 발현합니다.
• 점의 색상 강도: 해당 그룹 내에서 유전자의 평균 발현 수준(Mean expression in group)을 나타냅니다. 색상이 짙을수록 평균 발현 수준이 높습니다.

주요 관찰 내용은 다음과 같습니다:

• 정상 신장 상피세포 마커 (Diploid/Normal 조건): 'Diploid'로 표시된 정상 샘플(예: Diploid SI_18856, Diploid SI_22605)과 일부 비-이수성체(non-diploid) 정상 샘플(예: SI_22605, SI_21255)에서 공통적으로 높은 발현과 높은 세포 비율을 보이는 유전자 그룹이 뚜렷하게 관찰됩니다. 이들 유전자에는 BCAM, ITM2C, EMP1, TACSTD2, CLCNKB, DPEP1, SLC22A8, SLC6A13, SLC22A6, SLC13A1, SLC5A12, NOX4, PTH1R, SLC13A3, SLC22A12, SLC34A1, SLC7A9 등이 포함됩니다. 이들은 정상 신장 상피세포의 기능을 반영하는 마커들로 추정됩니다.
• 종양 신장 상피세포 마커 (Tumor 조건): 'tumor'로 표시된 샘플(예: SI_18854, SI_22604, SI_23843)에서 특이적으로 높은 발현과 높은 세포 비율을 보이는 유전자 그룹이 명확하게 구분됩니다. 이들 유전자에는 HLA-DRB1, HLA-DPA1, HLA-DPB1, MYADM, C5orf15, HLA-DQB1, SLC38A1, SERINC2, TMEM37, FAM174A, EMP3, BST2, SLC2A3, EGFR, TMED7, TNFRSF1A, TSPAN4, TNFRSF14, HM13, HLA-F, SLC6A8, GYPC, TFPI, EFNA1, CXCR4, SLC37A4, RNF149, VCAM1, CD70, SLC22A5 등이 포함됩니다. 이 유전자들은 종양 발생 및 진행과 관련된 변화를 나타낼 가능성이 높습니다.
• 조건 간의 뚜렷한 구분: 정상 샘플과 종양 샘플 간에 발현되는 표면 마커 유전자들이 매우 뚜렷하게 구분되어, 신장 상피세포가 종양 조건에서 매우 특이적인 표면 특징을 획득함을 시사합니다.

Biological Interpretation

신장 상피세포의 조건별 표면 마커 분석 결과는 정상 신장 기능과 신장암(Renal Cell Carcinoma, RCC) 발생 시 세포 표면의 주요 변화를 밝혀줍니다.

1. 정상 신장 상피세포의 특징 마커:

• 수송체 및 이온 채널 (SLCs, CLCNKB): SLC(Solute Carrier) 계열 유전자들(예: SLC22A8, SLC6A13, SLC13A1, SLC5A12, SLC34A1, SLC7A9, SLC22A12, SLC13A3)은 신장 세관에서 영양분, 이온, 유기 분자 등의 재흡수 및 분비에 필수적인 역할을 합니다. CLCNKB는 염화물 이온 채널로 신장의 염분 재흡수에 중요합니다. 이들의 발현은 정상 신장 상피세포의 주요 기능인 항상성 유지 및 물질 수송과 직접적으로 관련됩니다.
• DPEP1 (Dipeptidase 1): 신장 상피세포에서 발현되며 펩티드 가수분해에 관여합니다.
• PTH1R (Parathyroid Hormone 1 Receptor): 부갑상선 호르몬 수용체로, 신장에서 칼슘 및 인산염 항상성 조절에 중요합니다. GeneCards: PTH1R
• BCAM (Basal Cell Adhesion Molecule), EMP1 (Epithelial Membrane Protein 1): 세포 부착 및 구조적 통합에 기여할 수 있는 유전자들입니다.

2. 종양 신장 상피세포의 특징 마커:

• 주요 조직 적합성 복합체 Class II (MHC Class II) 유전자 (HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-F): MHC Class II 분자는 주로 항원제시세포에서 발현되어 T 세포에 항원을 제시하지만, 특정 염증 또는 암 조건에서 비-면역 세포에서도 이소적으로 발현될 수 있습니다. 신장 상피 종양 세포에서의 MHC Class II 발현 증가는 종양 미세환경 내의 면역 반응 조절 또는 종양 세포의 비정상적인 면역 상호작용을 시사할 수 있습니다. PubMed search: MHC Class II in cancer
• EGFR (Epidermal Growth Factor Receptor): EGFR은 세포 성장, 증식, 생존, 분화에 관여하는 수용체 티로신 키나아제입니다. 많은 암에서 EGFR의 과발현 또는 활성화는 종양 진행 및 전이와 관련되어 있으며, 신장암에서도 중요한 역할을 합니다. GeneCards: EGFR
• VCAM1 (Vascular Cell Adhesion Molecule 1), CXCR4 (C-X-C Motif Chemokine Receptor 4), EFNA1 (Ephrin A1): 이들은 세포 부착, 이동, 침윤, 혈관신생 및 전이와 관련된 분자들입니다. VCAM1과 EFNA1은 세포-세포 또는 세포-기질 상호작용에 관여하여 종양 세포의 이동성을 증가시킬 수 있습니다. CXCR4는 CXCL12 리간드와 결합하여 종양 세포의 전이성 이동을 촉진하는 데 중요한 역할을 하는 케모카인 수용체입니다. GeneCards: CXCR4
• CD70 (TNFSF7): TNF(Tumor Necrosis Factor) 슈퍼패밀리 리간드로, T 세포 활성화에 관여하며 암세포에서 발현될 경우 면역 회피 기전으로 작용할 수 있습니다.
• SLC2A3 (GLUT3): 포도당 수송체로, 많은 암세포에서 에너지 요구량 증가를 충족시키기 위해 포도당 흡수를 촉진합니다(Warburg 효과).
• BST2 (Bone Marrow Stromal Antigen 2/Tetherin): 면역 반응에 관여하며 암에서 종종 상향 조절되는 것으로 알려져 있습니다.

Clinical or Translational Implications

이 분석에서 식별된 신장 상피세포의 조건별 표면 마커는 신장암 진단, 예후 예측 및 치료 전략 개발에 중요한 의미를 가집니다.

• 진단 및 예후 바이오마커: 정상 신장 상피세포에 특이적인 SLC 계열 유전자나 종양 신장 상피세포에 특이적으로 과발현되는 EGFR, CXCR4, VCAM1, CD70, MHC Class II 분자 등은 신장암의 초기 진단, 병기 설정 및 예후 예측을 위한 유용한 바이오마커 후보가 될 수 있습니다. 혈액 또는 소변 샘플에서 이러한 표면 마커의 존재 또는 수준을 평가하는 액체 생검(liquid biopsy) 접근법을 개발하는 데 활용될 수 있습니다.
• 치료 표적 발굴: EGFR은 이미 여러 암종에서 표적 치료제(예: 티로신 키나아제 억제제) 개발에 성공한 주요 표적입니다. CXCR4는 암 전이 억제를 위한 약물 개발의 유망한 표적이며, VCAM1 및 CD70과 같은 분자들도 종양 성장, 전이, 면역 회피를 표적으로 하는 항체 치료제 또는 세포 치료제 개발에 활용될 가능성이 있습니다.
• 면역 치료 전략: 종양 세포에서 MHC Class II 분자의 이소성 발현은 종양 면역 반응의 복잡성을 시사합니다. 이는 면역 체크포인트 억제제와 같은 면역 치료법의 반응을 예측하거나, 종양 세포의 항원 제시 능력을 조절하여 면역원성을 높이는 새로운 치료 전략을 모색하는 데 단서를 제공할 수 있습니다.
• 약물 전달 시스템 개발: 종양 특이적 표면 마커는 약물을 종양 세포에 선택적으로 전달하는 표적 약물 전달 시스템(Targeted Drug Delivery System) 개발에 활용될 수 있습니다. 예를 들어, EGFR이나 CXCR4와 같은 과발현된 수용체에 결합하는 약물-항체 접합체(ADC)를 개발하여 정상 세포의 손상을 최소화하면서 종양 세포에 직접 약물을 전달할 수 있습니다.
• 추가 검증: 이러한 후보 마커들은 면역조직화학(immunohistochemistry), 유세포 분석(flow cytometry) 등을 통해 실제 신장암 조직 샘플에서 단백질 수준의 발현을 확인하고, 기능 연구를 통해 이들 마커가 신장암 발생 및 진행에 미치는 영향을 규명하는 추가적인 실험적 검증이 필요합니다.

16. Macrophage Condition-Specific Surfaceome Markers in Kidney Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify surfaceome markers that differentiate macrophages in kidney tumor samples from those in normal kidney tissue. Utilizing single-cell RNA sequencing data, the plot_markers_and_expression_dot tool was employed to visualize the expression patterns of the top 50 condition-specific surface markers for macrophages, prioritizing genes with high nz_pct_score, fold change (FC > 1.5), and adjusted p-value (p < 0.05). The focus on surfaceome markers is particularly relevant for identifying potential diagnostic or therapeutic targets accessible on the cell surface.

Visual Summary

The dot plot effectively visualizes the expression of macrophage surface markers across different kidney tissue samples, grouped by condition.

• Sample Grouping: The plot clearly delineates two groups of samples. The top three samples (SI_18856, SI_22605, SI_22369) exhibit generally low expression and fraction of cells expressing most of the identified markers, suggesting they represent macrophages from normal kidney tissue. The remaining samples, starting from SI_18854 and extending downwards, are explicitly labeled as "tumor" and demonstrate consistently higher expression and prevalence of a distinct set of surface markers.
• Expression Patterns: The color intensity (red scale) indicates the mean expression level of a gene within a sample group, with darker red signifying higher expression. The size of the dot represents the fraction of cells expressing the gene in that group.
• Tumor-Associated Macrophage (TAM) Signature: A prominent pattern is the strong enrichment of numerous surface markers in macrophages from tumor samples. These markers display high mean expression (darker red dots) and a large fraction of expressing cells (larger dot size) across virtually all tumor samples. In contrast, these same markers show minimal to no expression in macrophages from normal kidney tissue.
• Normal-Associated Macrophage Markers: Fewer surface markers show a strong, specific upregulation in normal kidney macrophages compared to tumor macrophages. FCGR3A and CD9 show some presence in normal macrophages, but the overall signature for normal-specific surface markers is less pronounced in this plot, indicating that the marker discovery favored tumor-associated genes or that normal kidney macrophages have fewer uniquely defining surface markers in this context.

Biological Interpretation

The analysis highlights a clear shift in the surfaceome profile of macrophages residing within the kidney tumor microenvironment (TME) compared to those in normal kidney tissue. This distinct surface marker signature in tumor-associated macrophages (TAMs) reflects their altered functional state and interaction with the tumor.

Key Tumor-Associated Macrophage Surface Markers and Their Biological Roles:

• CSF1R (Colony Stimulating Factor 1 Receptor): Highly and consistently expressed in TAMs. CSF1R signaling is crucial for macrophage survival, proliferation, and differentiation, making it a well-established target for modulating TAMs in cancer. GeneCards: CSF1R
• TREM2 (Triggering Receptor Expressed on Myeloid Cells 2): Shows strong expression in TAMs. TREM2 plays a role in phagocytosis, cell survival, and dampening inflammatory responses, and its expression on TAMs is often associated with pro-tumorigenic and immunosuppressive phenotypes in various cancers. GeneCards: TREM2
• FOLR2 (Folate Receptor Beta): Prominently expressed in TAMs. FOLR2 is a recognized marker for alternatively activated (M2-like) macrophages, which are often enriched in tumors and contribute to immunosuppression, angiogenesis, and tissue remodeling. UniProt: FOLR2
• MSR1 (Macrophage Scavenger Receptor 1 / CD204): Elevated in TAMs. MSR1 is involved in the uptake of modified lipids and other molecules, and its expression is often associated with M2-like polarization and tumor progression.
• GPNMB (Glycoprotein NMB): Highly expressed in TAMs. GPNMB is involved in cell adhesion, migration, and anti-inflammatory responses, and its overexpression has been linked to tumor progression and immune evasion.
• AXL (AXL Receptor Tyrosine Kinase): Shows increased expression in TAMs. AXL signaling promotes TAM survival, proliferation, and pro-tumorigenic functions, and can also contribute to resistance to various cancer therapies. GeneCards: AXL
• BSG (Basigin / CD147): Upregulated in TAMs. CD147 is a widely expressed glycoprotein that promotes tumor cell invasion and metastasis by stimulating matrix metalloproteinase production, and it is also involved in lactate transport and glycolysis. GeneCards: BSG
• CD14: While a general macrophage marker, its robust and widespread expression in TAMs compared to normal macrophages can indicate a dominant inflammatory or activated macrophage phenotype within the tumor.
• SIGLEC10 (Sialic Acid Binding Ig-like Lectin 10): Shows increased expression in TAMs. SIGLEC10 can interact with sialylated ligands to inhibit immune cell activation, contributing to immune evasion in the TME.
• IL10RB (Interleukin 10 Receptor Subunit Beta): Upregulated in TAMs. As a component of the IL-10 receptor, its higher expression suggests increased responsiveness to IL-10, a key immunosuppressive cytokine, further promoting an immunosuppressive TAM phenotype.
• FCGR1A (Fc Gamma Receptor Ia / CD64): Elevated in TAMs. CD64 is an activating Fc receptor whose expression can be induced by inflammatory cytokines like IFN-gamma, indicating an activated macrophage state.

Normal-Associated Macrophage Markers:

• FCGR3A (Fc Gamma Receptor IIIa / CD16): While generally present on various immune cells, its relatively higher prevalence in normal kidney macrophages and lower presence in tumor macrophages could suggest a shift in Fc receptor expression profiles in TAMs or the presence of specific macrophage subsets in normal tissue.
• The overall pattern indicates that macrophages in the kidney tumor microenvironment acquire a distinct, highly active, and often immunosuppressive phenotype, characterized by the upregulation of numerous surface receptors involved in immune modulation, cell survival, and interactions with other cells in the TME.

Clinical or Translational Implications

The identification of specific surfaceome markers on kidney tumor-associated macrophages holds significant clinical and translational potential:

• Therapeutic Targets: Genes like CSF1R, TREM2, FOLR2, AXL, and BSG are well-established or emerging therapeutic targets in oncology. Agents (e.g., small molecule inhibitors, antibodies) that block these receptors or target cells expressing them could be explored to deplete or reprogram TAMs, thereby dampening immunosuppression and enhancing anti-tumor immunity in kidney cancer. PubMed: Macrophage-targeted therapies in cancer
• Diagnostic and Prognostic Biomarkers: The differential expression of these surface markers could be harnessed for diagnostic purposes (e.g., characterizing tumor biopsies, liquid biopsies) or for prognostic stratification of kidney cancer patients. For instance, high expression of TREM2 or FOLR2 on TAMs might correlate with disease aggressiveness or poor response to certain therapies.
• Patient Stratification and Response Prediction: Understanding the specific surfaceome signature of TAMs could help stratify patients who are more likely to respond to TAM-targeting immunotherapies or combination approaches.
• Experimental Validation: The identified markers provide a robust list of candidates for further experimental validation. Techniques such as immunohistochemistry (IHC) or multiplex immunofluorescence on kidney tumor tissue sections could confirm protein expression patterns and spatial localization. Flow cytometry could be used to analyze these markers on macrophages isolated from tumor and normal tissues to further validate their differential expression at the protein level.
• Targeted Drug Delivery: Since these are surface markers, they could serve as specific "addresses" for targeted drug delivery systems that aim to selectively deliver payloads (e.g., chemotherapy, immunomodulators) to TAMs, minimizing off-target effects.

17. Condition-Specific Surfaceome Markers in CD4+ T cells in Kidney Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for CD4+ T cells derived from normal kidney tissue and renal tumor samples. The goal is to highlight differences in cell surface protein expression that may reflect distinct functional states or interactions of CD4+ T cells in these two environments. The analysis was performed using single-cell RNA sequencing data, focusing exclusively on surfaceome genes to identify potential targets for cell sorting, imaging, or therapeutic modulation.

Visual Summary

The dot plot visualizes the expression of selected surfaceome genes across CD4+ T cells from normal (SI_22369, 167 cells) and tumor (SI_22368, 601 cells) conditions. Each row represents a condition, and each column represents a gene. The size of the dot corresponds to the fraction of cells expressing the gene within that group, while the color intensity indicates the mean expression level.

Key observations from the plot include:

• Normal-specific Marker: AREG (Amphiregulin) is prominently expressed in CD4+ T cells from normal kidney tissue, showing high mean expression and a large fraction of expressing cells. Conversely, its expression is negligible in tumor-associated CD4+ T cells.
• Tumor-specific Markers: A broad set of genes, including components of the T cell receptor complex (CD3D, CD3G), MHC Class II molecules (HLA-DRA, HLA-DPB1, HLA-DRB1, HLA-DPA1), adhesion molecules (ICAM3, BSG, CD48), tetraspanins (CD37, CD53, CD63), and other functional surface proteins (CD7, CD74, ITM2B, CCR7, GYPC, LY6E, PIK3IP1, TMEM123), show significantly higher mean expression and a greater fraction of expressing cells in CD4+ T cells from tumor samples compared to normal tissue.
• Differential Expression Profile: There is a clear and robust differential expression pattern, indicating distinct surface protein landscapes for CD4+ T cells in healthy kidney versus the renal tumor microenvironment.
• Cell Count Difference: Notably, the number of CD4+ T cells identified in tumor samples (601 cells) is substantially higher than in normal tissue (167 cells), suggesting increased infiltration or expansion of these cells within the tumor microenvironment.

Biological Interpretation

The observed differential surfaceome expression provides valuable insights into the functional adaptation of CD4+ T cells in the context of renal cell carcinoma.

• AREG in Normal CD4+ T cells: The specific upregulation of Amphiregulin (AREG) in CD4+ T cells from normal kidney tissue is intriguing. AREG is a ligand for the Epidermal Growth Factor Receptor (EGFR) and plays roles in cell proliferation, survival, and tissue repair. While typically secreted, its presence as a surfaceome marker suggests it might be presented on the cell surface or play a contact-dependent role. In healthy tissue, AREG from CD4+ T cells could contribute to maintaining tissue homeostasis, immune regulation, or even promoting repair mechanisms, possibly through specific regulatory T cell or Th2 subsets. GeneCards AREG
• Activated/Immune Response Profile in Tumor CD4+ T cells: The robust expression of a wide array of surface markers in tumor-infiltrating CD4+ T cells (TILs) collectively points towards an activated, antigen-experienced, and highly interactive phenotype.
• TCR Complex (CD3D, CD3G): Consistent expression of these core components confirms their T cell identity and capacity for antigen recognition.
• MHC Class II Molecules (HLA-DRA, HLA-DPB1, HLA-DRB1, HLA-DPA1): While CD4+ T cells primarily recognize antigens presented by MHC Class II, their own expression of MHC Class II can occur upon activation. This suggests that these tumor-infiltrating CD4+ T cells might acquire antigen-presenting capabilities or are in a highly activated state within the tumor microenvironment, potentially interacting with other immune cells or even tumor cells that may aberrantly express MHC Class II. PubMed search: T cell MHC class II expression activation
• Chemokine Receptor (CCR7): CCR7 is critical for lymphocyte homing to secondary lymphoid organs. Its upregulation in tumor-infiltrating CD4+ T cells could indicate an influx of central memory T cells, naive T cells, or T cells with specific migratory programs. This might suggest ongoing recruitment or recirculation dynamics within the tumor. GeneCards CCR7
• Adhesion and Co-stimulatory Molecules (ICAM3, BSG, CD48): Upregulation of Intercellular Adhesion Molecule 3 (ICAM3/CD50) and Basigin (BSG/CD147) suggests enhanced cell-cell adhesion and communication. BSG is known to promote tumor invasion and metastasis, but also plays roles in T cell activation and matrix metalloproteinase (MMP) induction, pointing to complex interactions within the tumor. CD48 is involved in co-stimulation and adhesion, further indicating heightened cell-cell interaction. GeneCards ICAM3, GeneCards BSG
• Tetraspanins (CD37, CD53, CD63): These transmembrane proteins are involved in organizing signaling platforms on the cell surface, influencing cell adhesion, migration, and immune synapse formation, consistent with an activated and interactive state.
• Increased T cell Infiltration: The higher number of CD4+ T cells in tumor samples is consistent with immune cell infiltration into the tumor microenvironment, a common feature in many cancers, including renal cell carcinoma. The functional implications of this infiltration (anti-tumor vs. pro-tumor) would require further investigation into specific T cell subsets and their effector functions.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in CD4+ T cells hold several clinical and translational implications for kidney cancer:

• Biomarker Discovery: The distinct surfaceome profiles could be utilized as biomarkers. For instance, AREG could serve as a marker for healthy kidney-resident CD4+ T cells, distinguishing them from tumor-infiltrating populations. Conversely, the panel of highly expressed genes in tumor-associated CD4+ T cells (e.g., HLA-DRA/B/P, ICAM3, BSG, CCR7) could be used to characterize the immune microenvironment, potentially correlating with disease stage, prognosis, or response to therapy. These markers could be assessed by flow cytometry or immunohistochemistry in clinical samples.
• Therapeutic Targeting: Surface proteins highly specific to tumor-infiltrating CD4+ T cells represent potential therapeutic targets. For example, if a subset of these activated CD4+ T cells are found to be immunosuppressive (e.g., regulatory T cells) or exhausted, specific antibodies targeting their unique surface markers (e.g., BSG for its role in MMPs and T cell activation) could be developed to deplete or reprogram these cells, enhancing anti-tumor immunity. PubMed search: CD147 cancer immunotherapy
• Monitoring Immunotherapy: Changes in the expression of these markers on CD4+ T cells could be monitored in patients undergoing immunotherapy for kidney cancer. For example, a shift in the expression profile towards a more anti-tumor phenotype or a decrease in specific pro-tumorigenic markers could indicate treatment efficacy.
• Experimental Validation: The identified markers warrant further experimental validation using techniques like multiplex immunofluorescence, flow cytometry, or mass cytometry to confirm protein expression patterns and delve into the precise functional consequences of their differential expression in kidney cancer models and patient samples. This could involve sorting specific CD4+ T cell subsets based on these markers and performing functional assays (e.g., cytokine production, proliferation, cytotoxicity).

18. Renal Epithelial Cell Gene Ontology Analysis: Insights into Ploidy, Normal Physiology, and Tumorigenesis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results, specifically Gene Set Analysis (GSA), for Renal Epithelial cells derived from single-cell RNA-seq data. The analysis identifies biological pathways and processes that are significantly enriched (upregulated) in renal epithelial cells under three distinct comparative conditions:

1. Diploid vs. others: Comparing renal epithelial cells inferred to be diploid against those inferred to be aneuploid.
2. Normal vs. others: Comparing renal epithelial cells from normal kidney tissue against those from tumor tissue.
3. Tumor vs. others: Comparing renal epithelial cells from tumor tissue against those from normal kidney tissue.

The results are visualized as bar plots, displaying the top enriched GO terms (or pathways from other databases like KEGG, Reactome) ranked by their statistical significance (negative log10 of p-value and FDR-adjusted q-value).

Visual Summary

The three bar plots effectively illustrate distinct sets of enriched pathways for each comparison. Each plot displays approximately 60 top terms, ordered by their -log(p-val) on the left panel, with corresponding -log(q-val) on the right. High values for both -log(p-val) and -log(q-val) indicate strong and statistically robust enrichment.

• The Diploid_vs_others plot shows enrichment for pathways related to cell adhesion, signaling, protein processing, and a surprising number of cancer-associated pathways even in diploid cells.
• The normal_vs_others plot is dominated by metabolic processes, including oxidative phosphorylation and various amino acid/lipid metabolism pathways, alongside pathways associated with neurodegenerative diseases (likely reflecting fundamental cellular processes).
• The tumor_vs_others plot reveals a strong signature of protein synthesis and processing, inflammatory signaling, hypoxic response, and an striking array of infectious disease-related pathways.

The consistency between -log(p-val) and -log(q-val) for the top terms across all plots suggests that the identified enrichments are highly significant after multiple testing correction.

Biological Interpretation

Diploid Renal Epithelial Cells

Even within a complex tissue context like the kidney with tumor present, diploid renal epithelial cells exhibit distinct pathway enrichments.

• Cancer-associated pathways: The enrichment of "Pathways in cancer," "Proteoglycans in cancer," and "MAPK signaling pathway" suggests that even diploid renal epithelial cells in the tumor microenvironment may be undergoing changes associated with neoplastic transformation or are responding to oncogenic signals, perhaps representing a pre-malignant state or cells exposed to the tumor environment. Proteoglycans are key components of the extracellular matrix, often remodeled in cancer to facilitate growth and metastasis.
• Cellular structure and function: "Focal adhesion" and "Regulation of actin cytoskeleton" are crucial for cell-matrix interactions, cell migration, and maintaining epithelial architecture. Their enrichment indicates active modulation of cell shape and adhesion.
• Protein quality control: "Protein processing in endoplasmic reticulum" points to active protein synthesis and folding machinery, which can be a stress response or a fundamental requirement for cell function.
• Immune signaling and senescence: "Toll-like receptor signaling pathway" and "Cellular senescence" also appear, hinting at active innate immune responses or mechanisms to halt cell proliferation in response to stress or damage.

Normal Renal Epithelial Cells

Renal epithelial cells from normal kidney tissue are characterized by robust metabolic activity, which is essential for their physiological functions, such as filtration and reabsorption.

• High metabolic activity: "Oxidative phosphorylation" is a prominent enriched pathway, underscoring the high energy demands of renal epithelial cells. This is further supported by the enrichment of various catabolic pathways, including "Valine, leucine and isoleucine degradation," "Citrate cycle (TCA cycle)," "Pyruvate metabolism," and "Fatty acid degradation," indicating active utilization of diverse fuel sources (amino acids, carbohydrates, lipids) for ATP generation.
• Protein synthesis and homeostasis: "Ribosome" enrichment signifies active protein synthesis, crucial for maintaining cellular machinery and functions.
• Relevance of neurodegenerative/metabolic disease pathways: Terms like "Parkinson disease," "Huntington disease," "Alzheimer disease," and "Pathways of neurodegeneration" are repeatedly observed. These pathways are not directly indicative of kidney-specific neurodegeneration but rather highlight fundamental cellular processes (e.g., mitochondrial function, protein quality control, lipid metabolism) that are commonly disrupted in these diseases and are essential for maintaining overall cellular health and homeostasis in any metabolically active tissue like the kidney.

Tumor Renal Epithelial Cells

Renal epithelial cells from tumor tissue display a distinct pathological signature reflecting altered metabolism, increased cellular machinery, and an inflammatory/hypoxic microenvironment.

• Elevated protein synthesis and processing: A dominant theme is the enrichment of pathways involved in protein synthesis and processing, including "Ribosome," "Protein processing in endoplasmic reticulum," "Spliceosome," "Protein export," "Ribosome biogenesis in eukaryotes," "RNA transport," and "RNA degradation." This extensive machinery supports the rapid proliferation and altered protein demands of cancer cells.
• Inflammation and hypoxia: Key oncogenic signaling pathways are highly enriched: "NF-kappa B signaling pathway," "HIF-1 signaling pathway," and "TNF signaling pathway." NF-kappa B and TNF signaling are central to chronic inflammation, which is known to promote tumor growth and metastasis. HIF-1 signaling is critical for cells to adapt to hypoxia, a hallmark of rapidly growing solid tumors, by promoting angiogenesis and metabolic reprogramming PubMed: 25164805.
• Infectious disease signatures: A remarkable number of viral and bacterial infection pathways (e.g., "Coronavirus disease," "Salmonella infection," "Epstein-Barr virus infection," "Human T-cell leukemia virus 1 infection," "Pathogenic Escherichia coli infection") are enriched. This could indicate the presence of specific oncoviruses contributing to kidney cancer, or more generally, the activation of pathogen-associated molecular pattern (PAMP) recognition pathways and inflammatory responses that are hijacked by tumor cells, mimicking a persistent infection state to promote survival and immune evasion.
• Apoptosis regulation: "Apoptosis" pathway enrichment suggests active regulation of programmed cell death, which is often dysregulated in cancer to promote cell survival.

Clinical or Translational Implications

The distinct pathway enrichments in renal epithelial cells provide critical insights into kidney cancer biology and potential therapeutic strategies.

• Targeting Tumor Metabolism and Protein Homeostasis: The prominent upregulation of protein synthesis and processing pathways (ribosome, ER processing) in tumor cells suggests that targeting these processes could be effective in inhibiting tumor growth. Given the strong metabolic signature of normal renal epithelial cells, therapies that specifically disrupt altered protein synthesis or inflammatory pathways in tumor cells, while sparing normal metabolic functions, could have improved selectivity.
• Modulating Inflammation and Hypoxia: The activation of HIF-1, NF-kappa B, and TNF signaling pathways in tumor cells highlights their importance in driving tumor progression in renal cell carcinoma. Inhibitors of HIF-1 (e.g., agents targeting VEGF pathway, which is downstream of HIF-1, or HIF-2α inhibitors) GeneCards: HIF1A or NF-kappa B may represent valuable therapeutic avenues to disrupt tumor adaptation to hypoxia and chronic inflammation PubMed: 22895697.
• Role of Pathogen-like Responses: The striking enrichment of infectious disease pathways in tumor cells warrants further investigation. Understanding whether this represents actual viral/bacterial involvement or a cancer-driven mimicry of infection could open new avenues for immunotherapy or anti-infective-like strategies in kidney cancer.
• Biomarker Discovery: The identified gene sets could serve as a basis for developing diagnostic or prognostic biomarkers for renal cell carcinoma, particularly for distinguishing between normal and cancerous states, or even identifying subsets of diploid cells undergoing oncogenic changes.

19. 신장암 미세환경 내 주요 세포 유형별 유전자 세트 농축 분석

[Analysis Visualization Results]...

Analysis Overview

제공된 도트 플롯은 신장 조직에서 주요 세포 유형(Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, T cell CD4+, T cell CD8+)에 대한 유전자 세트 농축 분석(Gene Set Enrichment Analysis, GSEA) 결과를 보여줍니다. 각 세포 유형 내에서 정상(normal) 상태와 종양(tumor) 상태를 비교하거나, 신장 상피 세포(Renal Epithelial cell)의 경우 핵형(ploidy) 상태(Diploid vs. others)를 비교하여 조건별로 유의하게 상향 또는 하향 조절되는 유전자 세트를 시각화했습니다.

Visual Summary

• 도트 색상 (NES): 붉은색 계열은 해당 세포 유형 및 조건에서 유전자 세트가 상향 조절(양의 NES)되었음을 나타내고, 푸른색 계열은 하향 조절(음의 NES)되었음을 나타냅니다. 색이 진할수록 농축 정도가 강합니다.
• 도트 크기 (-log10(p-value)): 도트의 크기는 해당 농축의 통계적 유의성(p-value)을 나타내며, 도트가 클수록 더 유의미한(낮은 p-value) 농축을 의미합니다.

전반적인 패턴

• 'Renal Epithelial cell: tumor_vs_others' (종양성 신장 상피 세포)에서 가장 많은 수의 유전자 세트가 강하게 상향 또는 하향 조절되는 것이 관찰됩니다. 특히 'Renal cell carcinoma' 유전자 세트가 강하게 상향 조절되는 것이 두드러집니다.
• 면역 세포(Macrophage, T cell CD4+, T cell CD8+)에서도 종양 미세환경과 관련된 다양한 염증 및 면역 반응 관련 유전자 세트의 활성화가 나타납니다.
• 기질 세포(Endothelial cell, Smooth muscle cell)에서는 혈관 형성 및 혈관 수축 관련 유전자 세트가 종양 조건에서 활성화되는 경향을 보입니다.
• 'Renal Epithelial cell: Diploid_vs_others' (이배체 신장 상피 세포)의 경우, 종양 상피 세포에서 상향 조절되던 여러 유전자 세트가 하향 조절(푸른색)되거나 농축되지 않아, 종양 관련 특성이 주로 이배체가 아닌 다른 상태(예: 이수성 Aneuploid)와 연관될 수 있음을 시사합니다.

Biological Interpretation

이 분석 결과는 신장 종양 미세환경에서 각 세포 유형이 겪는 기능적 변화를 심층적으로 보여줍니다.

종양성 신장 상피 세포 (Renal Epithelial cell: tumor_vs_others)

• 암 발생 및 진행: 'Renal cell carcinoma', 'Wnt signaling pathway', 'Hippo signaling pathway', 'Rap1 signaling pathway' 등이 강하게 상향 조절되어, 신장암 세포의 증식, 생존, 전이 및 세포 운명 결정에 중요한 역할을 하는 신호 전달 경로가 활성화됨을 나타냅니다. Wnt와 Hippo 경로는 신장암에서 흔히 변형되며, 종양 형성 및 진행에 기여합니다 PubMed 검색: Wnt signaling kidney cancer, PubMed 검색: Hippo signaling kidney cancer.
• 대사 재편성: 'Pyruvate metabolism', 'Propanoate metabolism', 'Fatty acid degradation', 'Amino sugar and nucleotide sugar metabolism', 'Tyrosine metabolism', 'Valine, leucine and isoleucine degradation' 등이 상향 조절되어 암세포의 에너지 요구와 바이오매스 합성을 지원하는 대사 재편성이 발생함을 시사합니다. 이는 신장암의 특징적인 대사 변화 중 하나입니다 PubMed 검색: metabolic reprogramming kidney cancer.
• 신장 기능 손상: 'Proximal tubule bicarbonate reclamation', 'Vasopressin-regulated water reabsorption' 등 신장 특이적인 기능 관련 유전자 세트가 하향 조절되어, 종양화된 상피 세포가 정상적인 신장 기능을 상실함을 반영합니다.
• 세포 스트레스 및 노화: 'Cellular senescence'가 상향 조절되어 종양 형성 과정에서 세포 노화 관련 반응이 나타날 수 있음을 보여줍니다.

이배체 신장 상피 세포 (Renal Epithelial cell: Diploid_vs_others)

• 'Renal cell carcinoma' 및 여러 대사 관련 유전자 세트가 이배체 세포에서 하향 조절되는 경향은, 종양의 악성 특징과 대사 재편성이 주로 이배체가 아닌 이수성(aneuploid) 상태의 종양 세포에서 두드러지게 나타날 수 있음을 암시합니다. 이는 이수성이 신장암의 진행에 중요한 역할을 할 수 있다는 기존 연구 결과와 일치합니다 PubMed 검색: aneuploidy kidney cancer prognosis.

대식세포 (Macrophage: tumor_vs_others)

• 'Cytokine-cytokine receptor interaction', 'Antigen processing and presentation', 'Fc gamma R-mediated phagocytosis', 'Leukocyte transendothelial migration' 등이 강하게 상향 조절되어, 종양 미세환경 내 대식세포가 활성화되고 항원 제시 및 염증 반응에 관여하며 종양 침윤을 촉진할 수 있음을 나타냅니다. 이는 종양 관련 대식세포(TAM)의 특징적인 기능과 관련됩니다 GeneCards: FCGR3A.
• 대사 관련 유전자 세트(예: 'Pyruvate metabolism')의 상향 조절은 대식세포의 기능적 변화와 대사 재편성을 시사하며, 이는 M1/M2 표현형과도 연관될 수 있습니다.

T 세포 (T cell CD4+, T cell CD8+: tumor_vs_others)

• 'T cell receptor signaling pathway', 'Th17 differentiation' (특히 CD4+ T 세포), 'Natural killer cell mediated cytotoxicity' (특히 CD8+ T 세포) 등이 상향 조절되어 종양 미세환경 내 T 세포의 활성화와 세포 독성 기능이 증가함을 보여줍니다. 이는 항종양 면역 반응의 존재를 시사할 수 있습니다.
• 'Cytokine-cytokine receptor interaction' 및 'Leukocyte transendothelial migration'의 상향 조절은 T 세포의 종양 침윤 및 면역 조절 역할과 관련됩니다.
• 내피 세포 (Endothelial cell: tumor_vs_others) 및 평활근 세포 (Smooth muscle cell: tumor_vs_others):
• 'Cytokine-cytokine receptor interaction', 'Rap1 signaling pathway', 'Vascular smooth muscle contraction' 등이 상향 조절되어 종양 미세환경에서 혈관 신생 및 혈관 재형성이 활발하게 일어남을 나타냅니다. 내피 세포는 새로운 혈관을 형성하여 종양 성장을 지원하며, 평활근 세포는 혈관 구조 유지 및 조절에 기여합니다.

Clinical or Translational Implications

이 GSEA 결과는 신장암의 병태생리학적 메커니즘을 이해하고 잠재적인 진단 및 치료 표적을 식별하는 데 중요한 통찰력을 제공합니다.

표적 치료제 개발

• 종양성 신장 상피 세포에서 활성화된 Wnt, Hippo, Rap1 신호 전달 경로는 신장암 치료를 위한 새로운 약물 표적이 될 수 있습니다.
• 대사 재편성 관련 유전자 세트의 활성화는 암세포의 특정 대사 경로를 억제하는 대사 치료 전략의 가능성을 제시합니다.
• 면역 세포의 활성화된 유전자 세트는 면역관문억제제(immune checkpoint inhibitors)와 같은 면역 요법의 효과를 예측하거나, 새로운 면역 조절 인자를 발굴하는 데 활용될 수 있습니다.
• 바이오마커 발굴: 종양 조건에서 특정 세포 유형에서 고유하게 상향 또는 하향 조절되는 유전자 세트는 신장암의 진행, 예후, 또는 치료 반응을 예측하는 바이오마커로 개발될 수 있습니다.
• 병용 요법: 종양 미세환경 내 다양한 세포 유형 간의 상호작용을 고려하여, 예를 들어 혈관 신생을 억제하는 약물과 면역 반응을 강화하는 약물을 병용하는 등 다각적인 접근 방식의 근거를 마련할 수 있습니다.
• 핵형 분석의 중요성: 이배체 신장 상피 세포와 비이배체(예: 이수성) 신장 상피 세포 간의 유전자 세트 농축 차이는, 종양 이질성 및 핵형 상태를 고려한 개인 맞춤형 치료 전략의 필요성을 강조합니다. 핵형 분석은 종양의 공격성을 평가하는 데 추가적인 정보를 제공할 수 있습니다.

20. Discussion

The comprehensive single-cell analysis of kidney tissue elucidates the profound biological alterations occurring in Renal Cell Carcinoma (RCC), focusing on both the tumor cells themselves and the intricate immune microenvironment. A central finding is the robust identification of malignant renal epithelial cells, characterized by widespread aneuploidy and a distinct transcriptional signature. These tumor cells show activated oncogenic pathways like Wnt, Hippo, and Rap1 signaling, coupled with significant metabolic reprogramming to support their uncontrolled proliferation and survival. Concurrently, normal kidney-specific functions, such as proximal tubule bicarbonate reclamation, are significantly downregulated in tumor epithelial cells, reflecting the loss of tissue-specific identity during tumorigenesis.

The immune microenvironment of RCC is profoundly reshaped. Contrary to a common paradigm in many solid tumors where M2-like macrophages dominate, our data reveals a striking enrichment of M1 macrophages in tumor samples. This M1 dominance suggests a more pro-inflammatory and potentially anti-tumoral immune state, or at least a distinct polarization profile that warrants further functional investigation. Simultaneously, there is a statistically significant increase in the proportion of immunosuppressive regulatory T cells (Tregs) within the tumor, indicating an active mechanism of immune evasion that could counteract the potential anti-tumor effects of M1 macrophages and cytotoxic T cells, which are also abundant. The differential expression of surface markers on tumor-associated macrophages (TAMs), including CSF1R, TREM2, FOLR2, and AXL, further underscores their distinct phenotype and potential for therapeutic targeting. Similarly, tumor-infiltrating CD4+ T cells exhibit an activated, antigen-experienced phenotype with upregulation of MHC Class II molecules, suggesting complex immune interactions.

Cell-cell interaction analyses reveal a dramatic reprogramming of intercellular communication in the tumor microenvironment. Key interactions related to angiogenesis (e.g., VEGFA-FLT1/NRP1, PDGFB-PDGFRB), immune evasion (e.g., SIRPA-CD47, CD200-CD200R1, LAIR1-LILRB4), and extensive extracellular matrix remodeling (numerous collagen-integrin interactions) are highly upregulated. Of particular note is the dominant HBEGF-EGFR interaction between macrophages and aneuploid renal epithelial cells, suggesting a critical paracrine loop driving tumor cell proliferation. The recurrent amplification of EGFR in tumor cells identified through CNV analysis further reinforces its role as a key oncogenic driver. Unexpectedly, the Gene Ontology analysis for tumor renal epithelial cells also showed a striking enrichment of various infectious disease pathways, which may indicate a pathogen-mimicry strategy by tumor cells to promote inflammation or immune evasion, or even suggest the involvement of specific oncoviruses, requiring further investigation. These findings collectively highlight the multifaceted and dynamic interplay between tumor cells and their microenvironment, crucial for RCC progression and immune resistance.

Hypotheses:

1. The observed enrichment of M1 macrophages in the RCC microenvironment, despite an increase in Tregs, suggests a complex and potentially frustrated anti-tumor immune response where M1 macrophages are activated but their effector functions are suppressed by Treg-mediated mechanisms.
2. The HBEGF-EGFR paracrine loop between tumor-associated macrophages and aneuploid renal epithelial cells is a critical driver of tumor cell proliferation and survival in RCC, independent of or synergistic with intrinsic EGFR amplification within tumor cells.
3. The enrichment of infectious disease pathways in renal tumor epithelial cells represents a form of pathogen mimicry that promotes chronic inflammation and immune evasion, rather than actual active infection.
4. The presence of aneuploid cells in some "normal" kidney tissue samples indicates early pre-malignant changes or field cancerization, providing a window for early detection or prevention strategies.

Potential therapeutic targets:

1. EGFR signaling pathway (HBEGF-EGFR axis): Amplification of EGFR is a recurrent genomic alteration in RCC tumor cells. The HBEGF-EGFR interaction between tumor-associated macrophages and aneuploid renal epithelial cells represents a dominant, pro-tumorigenic paracrine loop driving tumor cell proliferation and survival in the tumor microenvironment. Evidence: CNV analysis (Section 4) shows recurrent EGFR amplification. CCI analysis (Section 13) identifies HBEGF_EGFR as the prominent macrophage-tumor cell interaction in tumor tissue. GSEA (Section 19) indicates activation of relevant signaling pathways in tumor cells. Renal Epithelial cell surface marker analysis (Section 15) confirms EGFR overexpression on tumor cells. Validation: Test EGFR tyrosine kinase inhibitors (TKIs) or HBEGF-blocking antibodies in RCC cell lines, co-culture models, and patient-derived xenografts. Confirm target engagement and evaluate effects on tumor growth, proliferation, and macrophage-mediated immune suppression. Validate EGFR protein expression and activation status via IHC/Western Blot in patient samples.
2. CD47-SIRPA axis: 'Don't eat me' signal frequently utilized by cancer cells to evade phagocytosis by macrophages. Highly active in tumor conditions. Evidence: CCI analyses (Sections 11, 12, 14) show strong and extensive SIRPA-CD47 interactions between renal epithelial cells (tumor cells) and macrophages in the tumor microenvironment. Validation: Evaluate anti-CD47 or anti-SIRPA antibodies in *in vitro* phagocytosis assays with RCC cells and macrophages, and in *in vivo* RCC models to assess macrophage-mediated tumor clearance and overall tumor growth inhibition. Validate CD47 and SIRPA protein expression on tumor cells and TAMs via flow cytometry/IHC in patient samples.
3. Tumor-Associated Macrophage (TAM) modulators (e.g., CSF1R, TREM2, FOLR2, AXL): Macrophages in the tumor microenvironment acquire a distinct, often immunosuppressive and pro-tumorigenic phenotype, characterized by unique surface markers. Modulating these TAMs can reprogram the immune microenvironment. Evidence: Macrophage surfaceome marker analysis (Section 16) reveals significant upregulation of CSF1R, TREM2, FOLR2, AXL, BSG, and IL10RB on TAMs in tumor samples. Validation: Test CSF1R inhibitors or antibodies targeting TREM2, FOLR2, or AXL in *in vivo* RCC models. Assess effects on TAM depletion/reprogramming (e.g., M1 vs. M2 markers), immune cell infiltration, and tumor growth. Confirm target protein expression and co-expression on TAMs via multiplex IHC/flow cytometry in clinical specimens.
4. Regulatory T cells (Tregs): Increased proportion of Tregs in the tumor microenvironment promotes an immunosuppressive state, hindering anti-tumor immunity. Evidence: T cell subset population analysis (Section 7) and boxplot (Section 8) show a statistically significant increase in Treg proportion in tumor samples. Validation: Investigate antibodies or small molecules that deplete or inhibit Treg function (e.g., targeting CTLA4, FOXP3, or Treg-specific surface markers like TNFRSF18) in combination with other immunotherapies in RCC models. Monitor Treg numbers and suppressive function. Confirm FOXP3 and CTLA4 protein expression via IHC/flow cytometry in patient samples.

Follow-up validation ideas:

1. Perform *in vitro* co-culture experiments with isolated RCC cells and macrophages, using cytokine stimulation to shift M1/M2 balance and assess impacts on tumor cell proliferation, migration, and immune cell cytotoxicity. Validate M1 functional markers (e.g., iNOS, TNF-alpha) via flow cytometry/immunostaining on patient samples.
2. Test specific EGFR inhibitors (e.g., TKIs) or HBEGF-blocking antibodies in *in vitro* RCC cell-macrophage co-cultures and *in vivo* patient-derived xenograft (PDX) models of RCC to evaluate effects on tumor growth, proliferation, and macrophage-mediated immune suppression. Targeted qPCR could confirm HBEGF and EGFR expression in patient samples.
3. Use flow cytometry and immunostaining on patient RCC samples to precisely quantify Treg populations and their activation status (e.g., FOXP3, CTLA4, PD-1). *In vivo* models with Treg depletion or blockade of Treg-specific surface markers (e.g., TNFRSF18) could assess the impact on anti-tumor immunity and tumor progression.
4. Apply spatial multi-omics technologies (e.g., Visium, GeoMx, CODEX) to kidney tumor tissues to precisely localize identified cell-cell interactions (e.g., SIRPA-CD47, collagen-integrins, HBEGF-EGFR, LAIR1-LILRB4) and confirm physical proximity of interacting cell types.
5. Perform FISH or whole-genome sequencing on aneuploid cells from "normal" samples to confirm CNV presence and investigate clonality. Validate EGFR amplification in tumor samples via FISH or ddPCR.
6. Utilize flow cytometry or immunohistochemistry to validate protein expression of immune checkpoint molecules (e.g., CD47, SIRPA, CD200, CD200R1, LILRB4, LAIR1) on TAMs and tumor cells in independent RCC cohorts.

Limitations:

This single-cell RNA-seq analysis provides a high-resolution snapshot of the kidney tumor microenvironment but carries inherent limitations. The cross-sectional nature prevents direct causal inference of observed associations. While CNV inference from RNA-seq provides valuable insights, it is an indirect measure and requires orthogonal DNA-based validation for definitive confirmation. Cell-cell interaction predictions are computational and necessitate experimental validation to confirm physical interactions and functional consequences. The categorization of 'unassigned' cells in tumor samples, although likely malignant based on context and ploidy, requires further specific marker identification to refine their annotation. Finally, transcriptomic data reflects gene expression, not always protein levels or direct functional activity, emphasizing the need for protein-level and functional validation experiments.

21. Query List

1. Show UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save.
2. Show major celltype scores on UMAP and save.
3. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
4. Select tumor origin cells and unassigned cells, group them by sample, show a CNV heatmap, and include a summary of significantly amplified copy number regions, then save.
5. Show CNV patterns as a UMAP. Include major cell type, minor cell type, ploidy results, condition, and sample in 2 columns and save.
6. Show a population bar plot of minor cell types and save.
7. Show a subset population bar plot for T cells and save.
8. For T cell subset populations, show a boxplot for statistically significant differences between conditions and save. Set ncols appropriately based on the total number of panels.
9. Show a subset population bar plot for Macrophages and save.
10. Select tumor origin cells and unassigned cells, show a ploidy population bar plot for them, and save.
11. Show cell-cell interaction patterns including Renal Epithelial cells (tumor origin cells), fibroblasts, macrophages, and T cells by condition, and save. Select up to 80 cell-cell interactions per condition.
12. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
13. Select only genes related to immune checkpoint pathways and cell cycle pathways, show cell-cell interactions for these genes, and save.
14. Find statistically significant differences in cell-cell interactions between conditions for major immune and stromal cells, show a dot plot, and save. Set max_n_items_per_group = 25.
15. Show the condition-specific markers for tumor-origin cells (Renal Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
16. Extract condition-specific markers for Macrophages, show a dot plot, and save. Include only surfaceome markers, up to 50 per condition.
17. Extract condition-specific markers for T cell CD4+, show a dot plot, and save. Include only surfaceome markers, up to 50 per condition.
18. Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
19. Show a dot plot of Gene Set Enrichment Analysis results for major cell types (Endothelial cell, Macrophage, Renal Epithelial cell, Smooth muscle cell, T cell CD4+, T cell CD8+), and save. Use color map RdBu_r and set n_pws_to_show = 80.